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HIV rapid antibody assays are important for screening children aged <18 months for 
HIV exposure and children ≥18 months for HIV infection. Limited available data 
indicate variable performance of different HIV rapid tests in comparison to 
laboratory HIV antibody assays. The aim of this study was to evaluate the diagnostic 
accuracy of 6 HIV rapid tests currently used in South Africa for screening children 
using whole blood.  
 
Methods 
A prospective descriptive cross-sectional laboratory study was conducted at two 
paediatric healthcare facilities in South Africa. Sensitivity and specificity analyses 
and positive and negative likelihood ratios were performed. The reference standard 
was the laboratory HIV enzyme-linked immunosorbent assay (ELISA) test and HIV 
polymerase chain reaction (PCR) test.   
 
Results 
Blood samples from 1159 children (896 <18 months of age) with valid HIV ELISA 
test results were included in the analysis. A total of 5768 HIV rapid tests (4446 in 
children <18 months of age) were performed. Sensitivity of HIV rapid tests for 
detecting HIV exposure among children <18 months of age ranged from 38.7% to 
94.7%. Four HIV rapid tests attained specificity in excluding HIV exposure among 
children <18 months of age of >98%. Seroreversion rates were lowest with the 
Determine rapid test. Three HIV rapid tests (Abon, Advanced Quality, Determine) 
detected 100% of HIV-infected children <18 months of age, the Reveal, SD Bioline 
and Insti rapid tests missed 27 (41.5%), 1 (4.5%) and 1 (1.5%) of the HIV-infected 
children respectively. In children ≥18 months of age, sensitivity of rapid tests for 










None of the 6 HIV rapid tests evaluated achieved both the World Health 
Organisation recommended sensitivity and specificity standards for any antibody 
assay used in screening for HIV exposure in children <18 months. The Determine 
test showed the best overall diagnostic accuracy and is therefore recommended as the 
preferred screening test for children. Recommendations on the use of specific HIV 
rapid tests in infants and young children should be based on evaluation of their 
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Figure 1. HIV testing algorithm, Western Cape (2008) 
 
Figure 2. Study HIV testing algorithm for children <18 months of age 
 
Figure 3. Study HIV testing algorithm for children ≥18 months of age 
 












HIV infection in infants (children <12 months of age) and young children is 
associated with high rates of morbidity and mortality. 1,2 In 2008, a randomised 
clinical trial demonstrated that initiation of combination antiretroviral therapy 
(cART) during early infancy is highly effective in reducing mortality and disease 
progression. 3 However, by 2010, infants comprised only 19% of all children who 
initiated cART across 12 Southern African treatment cohorts. 4 One of the obstacles 
to initiation of cART during early infancy is lack of access to reliable HIV diagnostic 
testing in resource-limited settings. In South Africa, which has relatively good access 
to early infant diagnosis (EID), significant progress has been made in prevention, 
diagnosis and treatment of paediatric HIV infection. In 2012, 83% of pregnant 
women received antiretrovirals (ARVs) for prevention of transmission, EID 
coverage reached 72.6%, the transmission rate in infants <2 months of age 
undergoing testing was 2.4%, and the estimated coverage of cART for HIV-infected 




During pregnancy, physiological transplacental passage of antibodies 
(Immunoglobulin G, IgG) from the pregnant woman to her foetus occurs. In a 
pregnant woman with HIV infection, HIV antibodies are transmitted to the foetus 
whereas the virus itself may or may not be transmitted to the foetus. Maternally 
derived antibodies may remain in the child’s circulation until 18 months of age and 
in some cases longer. Most commercially available HIV antibody tests, including 
HIV rapid tests (RTs), are able to detect antibodies in an infant or young child’s 
blood but are unable to distinguish between maternally-derived antibodies and 
antibodies produced endogenously by a child who has become HIV-infected. 7  
 
A positive HIV antibody test in a child of unknown HIV status who is <18 months of 




HIV infection in the child which requires further testing using HIV viral detection 
assays such as polymerase chain reaction (PCR) or p24 antigen testing. HIV-
uninfected children eventually lose maternal IgG antibody and revert to seronegative 
status (seroreversion) since there is no endogenous production of HIV antibody 
whereas in HIV-infected children, endogenous HIV antibody production occurs and 
the antibody test remains positive.  
 
A negative HIV antibody test in a child of unknown HIV status who is <18 months 
of age usually indicates either that the child is not HIV-exposed or that the child is 
HIV-exposed but has seroreverted. 8 If the child has never been breastfed or not 
breastfed during the past 6 weeks, the infant can generally be regarded as HIV-
uninfected. 9 If the child is still breastfeeding, a negative HIV antibody test does not 
exclude HIV infection at the time of testing as transmission of HIV infection from 
mother to child via breastmilk may occur. Diagnosis of HIV infection during 
breastfeeding generally requires the use of HIV viral detection assays in a child <18 




Although there is relatively rapid early decay of HIV-specific maternal IgG in the 
infant circulation (half-life 28-30 days), there is wide variation in the age at antibody 
loss (seroreversion) in HIV-exposed-uninfected children ranging between 
approximately 6 and 24 months in studies using different antibody assays and in 
different settings. 10-15 Although most studies report the majority of seroreversion 
occurring between 6 and 15 months, persistence of maternal IgG beyond 18 months 
of age has been reported. 10,13,15 In a 1994 report, three infants born to HIV-infected 
mothers were persistently negative on HIV antigen assays and HIV culture (and 
absolute T-cell numbers and ratios, and quantitative immunoglobulin levels were 
appropriate for age) but remained HIV antibody positive at 15 months and 18 
months before seroreverting at 18.5, 21 and 24.2 months respectively. They also 
remained clinically well and HIV antibody negative at 3, 4.5 and 5 years of age. 13 In 
a more recent study investigating the time of seroreversion among 744 infants born 




transmission, 14% of infants remained seropositive after 18 months, 4.3% after 21 
months, and 1.2% after 24 months. Maternal exposure to protease inhibitors was 
significantly associated with a later age of seroreversion. 15   
 
There is increasing evidence that early cART and virological suppression can affect 
the evolution of antibody responses to HIV infection. Failure to develop antibodies 
or seroreversion occurring in HIV-infected adults treated with cART during acute or 
early infection and in children following cART initiation during the first few months 
of life or after maintaining long-term viral suppression on cART has been 
reported.16-24 In children, this is particularly relevant in settings where confirmatory 
HIV testing using viral detection assays is limited or not available and a single viral 
detection assay or presumptive clinical criteria are used for diagnosis and initiation 
of cART in children <18 months of age. In this context, the World Health 
Organisation (WHO) recommends confirmatory testing using HIV antibody assays, 
including HIV RTs, at the age of 18 months. 9 Studies showing high rates of false-
negative HIV antibodies at 18 months - 2 years of age among children who started 
cART during infancy strongly suggest that HIV antibody tests cannot be used to 
reliably reconfirm HIV diagnosis in children starting early cART and may lead to 
uncertainties about the diagnosis of HIV infection and inappropriate discontinuation 
of cART. 18,20,21,24      
 
HIV antibody detection assays 
 
Antibodies to HIV can be detected using a variety of different techniques including 
enzyme immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA), rapid 
test devices and western blot (WB) tests. First-generation HIV ELISA tests became 
commercially available in 1985. Rapid advances in diagnostic technology led to the 
development of second and third-generation ELISAs that introduced recombinant 
protein and synthetic peptide antigens as well as new test formats.  These tests had 
improved sensitivity and specificity, ability to detect HIV-1, HIV-2 and HIV 
variants, and shortened the interval between infection and detection of antibodies 





Laboratory-based ELISA tests are designed for testing large batches of samples 
applicable to transfusion safety or surveillance programmes. The need for diagnostic 
testing in individuals in settings with limited laboratory facilities led to the 
development of highly sensitive and specific rapid tests including agglutination tests, 
immunocomb tests, immunodot tests using flow through membranes and 
immunochromatographic membrane tests. These simplified methodologies allow 
HIV testing to be carried out in primary care facilities by appropriately trained non-
laboratory personnel, including counsellors. Health care provider-initiated HIV 
testing can now include visibility of the test and quick turn-around times, increasing 
confidence in results and avoidance of clerical errors. Rapid tests allow for testing on 
whole blood (obtained via finger-prick or heel-prick in infants, or via venesection) or 
on plasma/serum where centrifugation facilities are available, and some HIV RTs 
can be used with oral fluid. 25-27 Table 2 summarises important differences between 
standard laboratory HIV ELISA tests and HIV rapid tests.  
 
Table 1. Comparison of standard laboratory HIV ELISA tests and HIV rapid tests  
[Adapted from Ref. 27] 
 
Feature Standard laboratory  
HIV ELISA test 
HIV rapid tests 
Detection 
method 
Detection of HIV antibodies in 
plasma/serum/oral fluid 




Skilled laboratory technician is 
required 
Any health care worker with basic 
training in performing the test 
Equipment Laboratory equipment including 
electricity is required  
Minimal, usually no additional 
equipment, reagents, running water or 
electricity is required 




More than 2 hours 1-20 minutes 
ELISA = enzyme-linked immunosorbent assay 
 
Western blot tests, initially used mostly for confirmatory testing, are based on a 
similar methodology to EIA but require sophisticated laboratory equipment and 
technical expertise. As a result of advances and simplification of other serological 





More recent advances have resulted in the development of combination assays that 
combine p24 antigen EIAs with traditional antibody EIAs. This allows for 
simultaneous detection of HIV antigen and antibodies in a single test and further 
reduces the window period in the detection of early or acute HIV infection. 9  
 
Since there is a wide range of commercially available HIV RTs, a number of factors 
must be considered in the selection of which testing kits to incorporate into an HIV 
testing programme. These factors include availability, cost, location of the testing 
site, specimen volume required for the assay, training requirements of personnel who 
will perform the tests, and the diagnostic performance of the test. Although many 
HIV RTs have undergone diagnostic performance evaluations in comparison to 
standard laboratory ELISA testing using stored adult plasma samples with known 
HIV results, performance evaluations in the detection of HIV antibodies in infants 
and young children is frequently lacking. In 2010, the WHO recommended that HIV 
antibody assays used for the purpose of clinical diagnostic testing in infants and 
children should have a minimum sensitivity of 99% and specificity of 98% under 
quality-assured, standardised and validated laboratory conditions, when used as a 
screening assay to determine HIV exposure in children <18 months of age or when 
used as a diagnostic assay in children >18 months of age. 9 
 
HIV testing strategies using antibody assays 
 
The WHO guidelines (2010) strongly recommend the use of HIV antibody assays to 
determine the HIV exposure status of all infants with unknown or uncertain HIV 
exposure at or around birth, the first postnatal visit (4-6 weeks of age) or any child 
health visit. At any age, infants with signs or symptoms suggestive of HIV infection 
should have an HIV antibody test and if positive a viral detection assay should be 
performed. In addition, it is recommended that well HIV-exposed infants should 
have HIV antibody testing at around 9 months of age (coinciding with the 
immunisation visit) and infants with a positive HIV antibody test should have a viral 
detection assay done to identify if they are HIV-infected and require cART. Children 




HIV antibody testing performed according to the standard diagnostic testing 
algorithm used in adults. 9 
 
An HIV testing algorithm describes the combination and sequence of specific HIV 
testing kits to be used within a given HIV testing strategy. The principle is that a 
carefully selected combination of different HIV RTs which have validated sensitivity 
and specificity characteristics (ideally the first test should be highly sensitive (≥99%) 
and the second test highly specific (≥98%)) used in an appropriate serial testing 
algorithm will have positive and negative predictive values comparable to or 
exceeding the traditional laboratory-based ELISA/WB approach. 9 Ideally, the same 
HIV RTs should be used for HIV testing of adults, children and infants, but in reality 
many HIV RTs have not undergone adequate performance evaluations in very young 
children (as screening tests for detection of HIV exposure and for detection of 
seroreversion amongst HIV-exposed children) in the particular contexts in which 
they are to be used.  
 
The risk of false-positive results increases the lower the HIV prevalence rate is in the 
population undergoing testing and the HIV testing algorithm that is selected must 
take this into account in order to minimise this risk. An HIV prevalence threshold of 
≥5% in the target population to be tested is what is recommended by WHO as 
acceptable to use a two-test serial antibody testing algorithm for the diagnosis of 
HIV infection in children ≥18 months of age and adults.9  
 
In a high HIV prevalence setting (≥5% in the target population), a first positive 
antibody test result should be confirmed with a second antibody test, using a 
different test kit on the same specimen. Two positive test results are indicative of a 
positive HIV antibody result. If test results are discordant (first test positive, second 
test negative), the specimen should be tested using a third test kit, different from the 
first two. If this result is negative, the sample is regarded as HIV antibody test 
negative. If the result of the third test is positive, the individual requires repeat 





In a low HIV prevalence setting (<5% in the target population), a first positive 
antibody test result should be confirmed with a second antibody test. If the first and 
second antibody tests are discordant (first test positive, second test negative), this is 
regarded as indicative of a negative HIV antibody result. If the first and second 
antibody tests are positive, the specimen should be tested using a third test kit to 
confirm a positive result. If the first and second test results are positive and the third 
is negative, the individual requires repeat testing three weeks later.9 
 
According to WHO guidelines, a negative HIV antibody screening test result 
excludes HIV infection in children ≥18 months of age, and in children <18 months 
of age indicates either that the infant is not HIV-exposed or that the infant is HIV-
exposed but has seroreverted.  If there has been no breastfeeding in the past 6 weeks, 
the infant is regarded as HIV uninfected. The WHO guidelines do not provide 
specific recommendations on the need for confirmation of negative HIV antibody 
screening test results in relation to the HIV prevalence in the target population. 9   
 
Current United States guidelines make a distinction between presumptive exclusion 
(based on a single negative HIV antibody test result in a non-breastfeeding infant or 
child ≥6 months of age) and definitive exclusion of HIV infection (based on 2 
negative antibody tests from separate specimens obtained at age ≥6 months provided 
the child has no other clinical or laboratory evidence of HIV infection and is not 
breastfeeding). 28-30 In recognition of data indicating that children with perinatal 
exposure aged 18-24 months may have detectable residual maternal HIV antibody, 
the most recent guidelines recommend that definitive exclusion or confirmation of 
HIV infection in children in this age group who are HIV antibody positive should be 
based on HIV nucleic acid testing. Diagnosis of HIV infection in children with non-
perinatal HIV exposure or children with perinatal exposure aged >24 months is 
primarily based on the use of HIV antibody testing although HIV nucleic acid testing 








Presumptive clinical diagnosis of HIV infection in children <18 months of age 
 
Laboratory assays that detect the virus or its components allow HIV infection to be 
definitively diagnosed before 18-24 months of age and facilitate early cART 
initiation. Nucleic acid amplification techniques such as qualitative or quantitative 
detection of HIV proviral DNA by PCR, or detection of viral antigen such as p24 
antigen have superseded older viral detection techniques such as viral culture. 
Although point-of-care devices have been developed, most virological detection 
tests, in particular PCR assays, require expensive laboratory infrastructure and 
trained personnel and are not available for routine care in all settings where testing is 
required.  
 
In settings where virological testing is not available, the WHO strongly recommends 
the use of clinical criteria (2 or more of oral thrush, severe pneumonia, severe sepsis, 
or a diagnosis of any AIDS indicator condition (Pneumocystis pneumonia, 
cryptococcal meningitis, severe wasting or severe malnutrition, oesophageal 
candidiasis, Kaposi sarcoma, and extra-pulmonary tuberculosis)) together with HIV 
antibody testing for the presumptive clinical diagnosis of severe HIV disease 
needing cART in infants and children <18 months of age. The guidelines indicate 
that an infant or child who meets these criteria has severe HIV disease and requires 
immediate cART with the requirement that the diagnosis of HIV infection should be 
confirmed using age-appropriate testing methods as soon as possible. It is 
recommended that serological testing should be repeated at 18 months of age to 
confirm HIV infection in the child but emphasise that access to early virological 
testing must be made available wherever possible to allow clinicians to implement 
improved diagnostic algorithms. 9  
 
A wide variety of observational studies have evaluated the accuracy of different 
clinical algorithms applied by different levels of healthcare workers in different 
health care contexts to study populations with different percentages of young infants 
and different HIV prevalence rates. 32-36 No single clinical diagnostic algorithm has 
proven to be highly sensitive and specific for diagnosis of HIV infection and they are 




reported sensitivities of clinical algorithms range between 9% and 89%, specificities 
between 42% and 99% and positive predictive values between 3% and 95%. 9 Table 
1 provides a summary of 2 of these studies. 33,34  
 
Table 2. The diagnostic performance of the Integrated Management of Childhood 
Illnesses (IMCI) and WHO Presumptive Diagnosis (WHO-PD) criteria with and 
without the addition of CD4 criteria for the diagnosis of HIV infection among infants 
and children <18 months of age in comparison to diagnosis by HIV 








































Spec: 43%  
Sens: 84% 










Sens: 80%  
Spec: 88%  
Sens: 77%  
Spec: 83%  
mo = months, [ ] = reference, Sens = Sensitivity, Spec = Specificity 
 
In South Africa, HIV PCR testing is available for confirmation of HIV infection in 
all HIV exposed children <18 months of age and is performed by the National 
Health Laboratory Service (NHLS). National guidelines make provision for HIV 
antibody testing to be done in children <18 months of age in order to determine 
whether or not a child is HIV exposed if the mother is not available and there is no 
record of her HIV status. For children ≥18 months of age, the guidelines recommend 
that HIV testing should follow the adult testing algorithm. If the HIV RT is positive, 
as second different HIV RT should be used for confirmation. If the second HIV RT 
is positive, the child is regarded as HIV positive whereas if the second HIV RT is 
negative, an HIV ELISA test should be submitted to the laboratory in order to 
establish the child’s HIV status. 37 
 
The guidelines indicate that a negative antibody detection test at any age excludes 
infection provided the child was last breastfed ≥6 weeks before the test and has no 
clinical signs of HIV infection. However, there is no mention of which HIV rapid 




2010, the WHO highlighted the need for further research on the performance of 
different HIV antibody assays in infants and children <2 years of age and this study 





LITERATURE REVIEW ON HIV RAPID TESTS (RT) IN CHILDREN 
 
A directed electronic search of the relevant literature was performed using Pubmed® 
(accessed via University of Cape Town (UCT) Libraries website). The objective of 
the literature review was to identify and describe published research on the 
performance of HIV rapid antibody tests in comparison to laboratory HIV ELISA 
and HIV PCR testing in children, particularly in infants and very young children. All 
study designs were included and the search was limited to English language articles. 
The search strategy included the following search terms: human immunodeficiency 
virus or HIV, rapid test or rapid testing or rapid antibody test, infant, child, early 
diagnosis or early infant diagnosis, diagnostic accuracy, seroreversion.  Article 
abstracts were scanned and relevant full text articles (7) were downloaded via UCT 
Libraries (http://www.lib.uct.ac.za/). Additional articles (5) were obtained by cross-
referencing the articles included and relevant conference abstracts (2) were also 
included. The literature review was not continued beyond the end of December 2014. 
 
Children older than 18 months of age 
 
Evaluations of the performance characteristics and diagnostic accuracy of HIV RTs 
in comparison to laboratory HIV ELISA and HIV virological detection assays have 
mostly involved adult populations. Some variability in the performance of different 
HIV RTs used under field conditions has been reported, however most third-
generation HIV RTs have reported sensitivities and specificities of between 94 and 
100% and 88 and 99.4% respectively in comparison to laboratory HIV ELISA.27,38-40  
 
In children older than 18 months of age, the performance of HIV RTs for the 
diagnosis of HIV infection has generally been reported as equivalent to adults 
although there are a very limited number of published studies and HIV RT assays 
evaluated. 
 
De Baets et al. evaluated alternative tests and strategies to simplify paediatric HIV 
screening in an African district hospital in 2003.41 The study included 788 children 




reference testing algorithm for children older than 18 months of age incorporated 
three laboratory HIV antibody assays: Vironostica HIV Uni-Form II Plus O 
(bioMe´rieux bv, Boxtel, The Netherlands), Enzygnost Anti-HIV 1/2 Plus (Dade 
Behring Marburg GmbH, Marburg, Germany), and INNO-LIA HIV (Innogenetics 
S.A., Ghent, Belgium) on the same sample of venous plasma. An HIV-negative 
status was based on the first test or two of the three tests being negative. An HIV-
positive status was based on two positive tests. An HIV viral load (VL) test (Cobas 
AmpliPrep/Amplicor HIV-1 [V1.5]; Roche, Branchburg, N.J.) was performed on 
each HIV-positive patient and was above 50 copies/ml in all cases, confirming the 
diagnosis of HIV infection. The HIV prevalence rate in the study population was 
3.9%.  
 
The proposed alternative screening strategy used serial HIV RTs selected because of 
characteristics that made them suitable for use in an African setting and performed 
on the same sample of capillary blood stored in ethylenediaminetetraacetic acid 
(EDTA) tubes. The Determine HIV-1/2 test (Abbott Laboratories, Tokyo, Japan) 
was done as the initial screening test. If the Determine test was negative, the patient 
was regarded as HIV-negative. If the Determine test was positive, the InstantScreen 
Rapid HIV-1/2 test (Gaifar GmbH, Potsdam, Germany) was performed and if 
positive the patient was regarded as HIV-positive. This differs from WHO 
recommendations which propose the use of a third HIV antibody test to confirm two 
positive results in a low HIV prevalence setting.9 According to the testing algorithm, 
if the Determine test result was indeterminate (1.3% of tests done), the InstantScreen 
test was done and if positive this was followed by the Uni-Gold HIV test (Trinity 
Biotech PLC, Bray, Ireland). However, all the indeterminate Determine tests were 
negative on further testing with InstantScreen.  
 
The alternative screening strategy had a sensitivity of 100% (95% confidence 
interval (CI) 99.5 to 100%) and a specificity of 100% (95% CI 99.5 to 100%) in 
comparison to the reference testing algorithm. Additional analysis of the Determine 
test results showed that there were no false-negative results and 2 false-positive 





The authors concluded that the use of a testing algorithm based on serial HIV RTs 
performed on capillary blood stored in EDTA tubes (obtained by finger-prick using 
glucolet capillary phlebotomy devices as opposed to the reference testing algorithm 
which used venous plasma obtained by venesection and centrifugation) instead of 
laboratory-based HIV ELISA assays performed as well in children older than 18 
months of age as in adults. This approach could simplify HIV diagnosis in children 
allowing same-day receipt of test results at lower costs and facilitate decentralisation 
of HIV screening. The study was performed in a low HIV prevalence setting (3.9%) 
which may have led to the increased risk of false-positive results (although still low 
at 0.3%) and therefore warranted repeating in a higher HIV prevalence setting. The 
authors also highlighted the value of HIV RTs in excluding HIV infection as there 
were no false-negative Determine test results although it is important to establish 
whether breastfeeding has been stopped. 
 
Sherman et al. 2012, evaluated the diagnostic performance of 5 HIV RTs (First 
Response HIV Card 1-2.0 (Premier Medical Corporation, Daman, India); Pareekshak 
HIV-1/2 Triline Card (Bhat Biotech, Bangalore, India); Abbott Determine HIV-1/2 
(Abbott Laboratories, North Chicago, IL); Smart Check HIV-1/2 (World 
Diagnostics, Inc., Miami, FL) and Insti HIV-1 (BioLytical Laboratories, British 
Columbia, Canada) using whole blood in a multisite cross-sectional HIV diagnostic 
study in South Africa which included children older than 18 months of age.42 The 
HIV prevalence rate amongst the children older than 18 months of age was much 
higher than in the De Baets study and ranged from 43-64% amongst the sub-groups 
tested with different HIV RTs. Children receiving cART were excluded.  
 
In comparison to third and fourth generation laboratory HIV ELISA tests (HIV-
1/HIV-2 III Plus, IMx System and AxSYM HIV Ag/AbCombo, respectively, Abbott 
Diagnostics Division, Wiesbaden, Germany), all 5 HIV RTs were 100% sensitive in 
detecting HIV-infected children. First Response, Pareekshak and Smart Check were 
100% specific in excluding HIV infection in uninfected children over 18 months of 
age, but the Determine and INSTI RTs each gave one false-positive result (Table 3.) 




test for HIV diagnosis in children over 18 months of age and First Response, 
Pareekshak or Smart Check would be suitable confirmatory tests.  
 
Table 3. Sensitivity and specificity of various HIV rapid tests in comparison to 
standard laboratory HIV ELISA for diagnosis of HIV infection in children >18 
months of age 
 





Sherman, 2012 [42] 
 
Sensitivity %  
(95% CI) 
Specificity %  
(95% CI) 
 









































95% CI = 95% confidence interval, [ ] = reference 
 
Children younger than 18 months of age 
 
In this age group, the performance of HIV RTs both for the detection of HIV 
exposure (indicating the need for further virological testing if available) as well as 
for the exclusion of HIV infection (either where the maternal HIV status is not 
known or by demonstrating seroreversion in HIV-exposed children) requires 
evaluation. The sensitivity of HIV RTs in children <18 months of age is the ability to 
detect HIV exposure as compared to laboratory HIV ELISA testing. The specificity 
of HIV RTs is the ability to correctly identify HIV-uninfected children (including 
seroreversion). The ability of an HIV RT to not miss any HIV PCR positive children 
<18 months of age is another important criterion to be evaluated. 
 
Detection of HIV exposure and exclusion of HIV infection by HIV RT 
 
Table 4 summarises the 2 most important studies, both performed in South Africa, 








Table 4. Sensitivity and specificity of various HIV RTs in comparison to standard 
laboratory HIV ELISA for detection of vertical HIV exposure in children ≤18 
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95% CI = 95% confidence interval, N/E = not evaluated, [ ] = reference, mo = months 
 
Sherman et al. 2008, evaluated the performance of 7 different HIV RTs in 
comparison to laboratory HIV ELISA at four ages (1.5, 3, 7 and 12 months) during 
infancy for detecting HIV exposure (sensitivity) and seroreversion (specificity).43 
The study used 2266 stored plasma and serum samples from 116 HIV-exposed 
infants of known HIV status (21 HIV-infected and 95 HIV-uninfected) who had been 
enrolled in an HIV diagnostic study in South Africa. All infants had only been 
exposed to single-dose nevirapine at delivery and no other ARVs. The definitive 
HIV status of each infant was determined with at least 2 HIV DNA PCR tests 
(Roche Amplicor version 1.5, Roche Molecular Systems, Basel, Switzerland) during 
study visits at 6 weeks, and 3-, 7- and 12 months of age. Surplus plasma and serum 




IMx System, Abbott Diagnostics Division, Wiesbaden, Germany) respectively were 
stored at −70⁰C. 
 
The RTs evaluated were selected as follows: Abbott Determine HIV-1/2 (Abbott 
Laboratories, Illinois, USA) and UniGold (Trinity Biotech, Co Wicklow, Ireland) 
because of published good performance in children older than 18 months; First 
Response HIV Card 1-2.0 (Premier Medical Corporation, Daman, India), Smart 
Check (Globalmed, Vancouver, USA) and Pareekshak HIV-1/2 Triline Card (Bhat 
Biotech, Bangalore, India) because they had been validated in adults and were being 
used in South Africa at the time of the study; Oraquick test (OraSure Technologies, 
Pennsylvania, USA) because additional experience using plasma and serum samples 
to complement previously published data on oral fluid testing was needed; and Insti 
HIV-1 RT (BioLytical Laboratories, British Columbia, Canada) because the testing 
time with this RT was 1 minute instead of the usual 10-20 minutes.  
 
From the 2266 samples, 1993 had HIV ELISA positive results and 273 (all from 12-
month-old infants) had HIV ELISA negative results. Not all infants had sufficient 
stored sample to perform all 7 HIV RTs but each HIV RT was evaluated on a median 
of 40 (range 34-42) and 285 (range 277-287) samples from HIV-infected and HIV-
uninfected infants respectively. Weakly positive HIV RT results were reported as 
positive. If HIV RT and HIV ELISA results did not concur, the HIV RT was 
repeated and if the results remained discordant, the HIV ELISA test was repeated on 
the stored sample to pick up recording errors or antibody loss during storage.  
 
An important finding of this study is that the 7 HIV RTs evaluated did not perform 
equally in the detection of HIV-exposure during the first 12 months of age. During 
the first 3 months of age, the sensitivity of all the HIV RTs was similar to HIV 
ELISA but thereafter only 1 HIV RT, Determine, maintained sensitivity (99.7%) 
within the WHO recommended range of 99-100% for HIV screening assays. The 
overall sensitivity of the other HIV RTs ranged between 70.3 and 81.3%.  
 
There were 275 samples from the 21 HIV-infected infants and 271 (98.5%) of these 




infants who had available stored sample only at 3 months of age. Both infants were 
negative on Unigold and OraQuick testing. One of the infants had sufficient sample 
for retesting and the repeat tests remained negative. There was insufficient sample to 
repeat the HIV ELISA test. The remainder of the negative HIV RT results among 
HIV ELISA positive samples were from 95 HIV- exposed but uninfected infants. 
Unigold, First Response and Insti each had a negative result at 3 months of age or 
younger which would have resulted in these 3 HIV-exposed uninfected infants being 
undetected. None of the HIV RTs detected seroreversion at 3 months of age but by 7 
months the different sensitivities of the 6 HIV RTs other than Determine when 
compared to HIV ELISA was seen.  
 
When comparing the HIV RT results to the HIV ELISA negative results at 12 
months of age, there were no false-positive HIV RT results except for 7 infants who 
had seroreverted according to ELISA but remained positive on the Determine RT 
emphasising the high sensitivity of this test.  
 
The specificity of the HIV RTs (ability to correctly exclude HIV infection) was 
assessed on 1991 samples from 95 HIV-uninfected infants. At 12 months of age, 
40% of these HIV-uninfected infants still had positive HIV ELISA tests, 50% were 
still positive on the Determine RT, and only 0-6% of the remaining 6 HIV RTs were 
still positive. 
 
Another important finding of this study is that the HIV ELISA test was positive in all 
HIV-exposed infants at 7 months of age or younger but by 12 months of age had a 
negative predictive value (NPV) of 100%. Apart from Unigold and OraQuick which 
didn’t detect 2 HIV-infected infants at 3 months of age, all the other HIV RTs had a 
NPV of 100%. This finding is of clinical significance as it implies that a negative 
HIV RT selected on the basis of the performance described in this study may be used 
to accurately exclude HIV infection in an infant.  
 
As would be expected, the positive predictive value (PPV) of HIV ELISA or HIV 
RT remains low (<20%) at 3 months of age or younger. By 7 months of age, the PPV 
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of HIV ELISA and Determine are still low (median 16%) but the median PPV of the 
other HIV RTs increased to 41% (at 7 months) and 80% (at 12 months).     
The authors concluded with the observation that the selection of which commercially 
available HIV RTs should be used for HIV screening of infants must be based on 
evaluation of the HIV RTs in the infant population and not extrapolated from adult 
data as not all HIV RTs perform equally across infancy. They also highlighted the 
need for further evaluations of HIV RT performance in infants on whole blood rather 
than stored plasma and in less-controlled field conditions rather than laboratory 
conditions.  
In a subsequent study, Sherman et al. evaluated the accuracy of 5 HIV RTs for 
detecting HIV exposure in early infancy and excluding HIV infection in HIV-
exposed infants using whole blood.42 Blood samples were obtained from children 
enrolled in a multisite cross-sectional study at 3 university hospitals, 6 primary 
healthcare clinics and an adoption centre in Johannesburg, South Africa. Children 
receiving ART were excluded. The HIV RTs initially included were First Response 
HIV Card 1-2.0 (Premier Medical Corporation, Daman, India) and Pareekshak HIV-
1/2 Triline Card (Bhat Biotech, Bangalore, India), both of which were in use in 
South African public health-care facilities at the time of the study; and Abbott 
Determine HIV-1/2 (Abbott Laboratories, North Chicago, IL), previously shown to 
be highly sensitive using plasma. During the study, the Smart Check HIV-1/2 
(World Diagnostics, Inc., Miami, FL) RT was added and later Insti HIV-1 
(BioLytical Laboratories, British Columbia, Canada) was also included because of 
its short testing time of 1 minute. The HIV RT s were performed in the order 
described. Laboratory-based testing included third and fourth generation HIV ELISA 
(HIV-1/HIV-2 III Plus, IMx System and AxSYM HIV Ag/Ab Combo, respectively, 
Abbott Diagnostics Division, Wiesbaden, Germany) and the HIV-1 DNA PCR assay 
(Roche Amplicor HIV-1 DNA PCR version 1.5, Roche Molecular Systems, Basel, 
Switzerland). Two reactive HIV ELISA results defined HIV exposure in children 
aged 18 months or less. The HIV infection status of children less than 18 months of 
age was determined by the DNA HIV PCR assay. The results of the various HIV 
RTs were compared against these reference standards. 
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There were 737 children ≤18 months of age and the prevalence of HIV infection 
amongst the children ranged from 7.5 – 37% across different age groups. The 
sensitivity of the HIV RTs for detection of HIV exposure ranged from 84.6 – 95.7% 
with Insti and Determine performing the best. The sensitivity was higher in children 
<3 months of age than in older children. Importantly, not all HIV-infected children 
were detected by the HIV RTs. Among infants >8 months of age, all the HIV RTs 
except the First Response test, were able to accurately exclude HIV infection if 
combined with a clinical assessment for overt clinical features of HIV infection 
(collected at enrolment). In infants <3 months of age, Determine showed the highest 
sensitivity for detecting HIV exposure of 99.3%, but it missed 1 HIV-infected infant, 
whereas Insti and Smart Check showed lower sensitivities for detecting HIV 
exposure but detected all of the HIV-infected children. First Response and 
Pareekshak showed the lowest sensitivity for detecting HIV exposure in infants <3 
months of age, and they missed the greatest number of HIV-infected infants. 
Among 138 ELISA-negative children ≤18 months of age, there was 1 false-positive 
Determine (specificity 99.2% [95% CI: 95.6 – 99.9]) and 2 false-positive Insti 
(specificity 96.2% [95% CI: 87.0 – 98.9]) results. First Response, Preekshak and 
Smart Check were 100% specific. 
Regarding seroreversion (negative HIV RT result in HIV-exposed [ELISA positive] 
but uninfected [PCR negative] children), rates were less than 20% below 4 months of 
age, 50% by 4-6 months of age with all HIV RTs except Determine, and 100% after 
8 months of age with all of the HIV RTs except Determine. Insti did not miss any 
HIV-infected children and was the most accurate HIV RT for detecting seroreversion 
after 6 months of age.     
This study showed that in the first 3 months of life, Determine was the only HIV RT 
of the 5 evaluated which attained the WHO recommended sensitivity cut-off of 
≥99% for clinical diagnostic testing, in this context used as a screening assay to 
detect HIV exposure. For all children ≤18 months of age, none of the HIV RTs 
achieved a sensitivity for the detection of HIV exposure of >96% and therefore 
failed to meet WHO recommendations. This can be explained by the increasing rate 
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of seroreversion as children approach 18 months of age. In this study, all 5 HIV RTs 
detected 100% seroreversion in children >10 months of age. Reliable detection of 
seroreversion well before 18 months of age is desirable to avoid the risk of 
incorrectly labelling a child as HIV-infected by HIV RTs at ≥18 months of age. The 
authors recommended that further evaluation of the sensitivity of HIV RTs for 
detection of HIV exposure in the age group 4-18 months was warranted as this study 
included relatively low numbers of children in this age group.  
The specificity for detecting HIV exposure attained the WHO recommendation of 
≥98% for all of the HIV RTs except Insti (96.2%). The authors also noted that their 
results highlighted the reduced sensitivity of HIV RTs on whole blood in this study 
compared to stored serum or plasma in a previous study. This is an important 
consideration in the selection of HIV RTs for use in paediatric testing programmes 
as capillary blood (whole blood) obtained from finger- or heel-prick sampling may 
be more practical than venesection and centrifugation in primary care settings.   
In an unpublished Kenyan study, the performance of Determine and Bioline RTs was 
assessed on whole blood of 9-month old HIV-exposed infants.44 In this study, the 
seroreversion rate was 90% but amongst the HIV-infected infants, the detection rate 
using Determine and Bioline was 72% and 83% respectively, significantly lower 
than the WHO recommended threshold of 99%.  
In another unpublished study from Botswana, Determine RT detected 100% of HIV-
infected infants less than 18 months of age but the Unigold RT detected only 87%.45
Detection of HIV-exposed and –infected children by HIV RT 
An important role for HIV RTs in children <18 months of age is the ability to detect 
and not to miss HIV-exposed (HIV ELISA-positive) and –infected (HIV PCR-
positive) children. Table 5 summarises 3 important studies that have evaluated the 
performance of various HIV RTs in detecting HIV-exposed and –infected children 




Table 5. Summary of published studies on the performance of various HIV rapid 
tests for detection of HIV-exposed and –infected (HIV ELISA+ HIV PCR+) children 












De Baets, 2005 
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(≤18 mo of age) 
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PCR= polymerase chain reaction, N/E = not evaluated, [ ] = reference, mo = months 
 
De Baets et al. reported that among 116 samples from children <18 months of age 
(mean age 9.7 ±4.9 months) with an HIV prevalence of 8.5%, there were no false 
negative (only three false-positive) Determine RT results using DNA PCR 
performed on dried blood spots stored on filter paper as the reference standard and 





Menzies et al. investigated the cost-effectiveness of incorporating initial screening 
with HIV RTs into a conventional infant HIV testing algorithm as a means of 
screening-out HIV-uninfected infants and thereby reducing the need for costly HIV 
virological detection assays.46 The HIV RTs used in the modified testing algorithm 
were either HIV 1/2 Determine (Abbott Laboratories, Abbott Park, IL) or HIV 1/2 
Stat-Pak (Chembio Diagnostics, Medford, NY), both of which were being used in 
Uganda’s adult HIV RT algorithm, and the conventional testing programme used 
Roche Amplicor HIV-1 DNA-PCR v1.5 (Roche Diagnostic Systems, Inc., 
Branchburg, NJ). HIV prevalence, RT sensitivity and specificity, and cost were 
analysed from a cohort of 788 HIV-exposed children aged 1.5 to 18 months who 
were attending 2 postnatal HIV screening programmes in Uganda. There were 202 
HIV PCR positive children (HIV prevalence 25.6%), 58 were tested with Determine 
and 144 with Stat-Pak. Sensitivity in comparison to the HIV PCR result was 93.1% 
(95% CI: 83.3%–98.1%) and 93.8% (95% CI:88.5%–97.1%) for Determine and Stat-
Pak respectively. The authors ascribed the reduced sensitivity of the HIV RTs to the 
high HIV incidence in a breastfeeding population and the possibility of infants being 
in the window period for HIV infection. The cost-effectiveness model estimated that 
incorporation of these 2 HIV RTs into screening excluded HIV infection from 3 
months of age or older in a more cost-effective manner than virological assays. 
 
In the study by Sherman et al. 2012, one of the objectives was to compare the 
performance of 5 HIV RTs in detection of HIV PCR positive children ≤18 months of 
age using whole blood and to assess whether the HIV RTs would miss any HIV-
infected children. 42 All of the HIV RTs except Insti missed HIV-infected infants of 
all ages and there was considerable variability by HIV RT and across different age 
groups (Table 5).   
 
Buchanan et al. also assessed the utility of HIV RTs to exclude HIV infection among 
infants and children ≥2 to <18 months in a low-resource setting in Tanzania where 
HIV nucleic acid amplification tests (NAATs) are not routinely available.47 The 
study included children who had been admitted to hospital with an acute febrile 
illness and enrolled in an observational study on invasive bacterial infection. At the 
time of enrolment in the initial study, Capillus (Trinity Biotech, County Wicklow, 
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Ireland) and Determine (Abbott Laboratories, Abbott Park, IL, USA) RTs were 
performed at the bedside by nurses trained and supervised by the study medical 
team. Children in whom both HIV RTs were positive underwent HIV NAAT 
(Abbott Real-Time m2000 System, Abbott Molecular, Illinois, USA), children with 
discordant HIV RT results had HIV ELISA (Vironistika Uniform II Plus-O Test, 
bio-Mérieux, NC, USA), but no further testing if negative on HIV ELISA. Children 
with two negative HIV RT results also had no further testing at the time of the initial 
study.  
The present study tested samples without prior HIV NAAT from the original 2006 to 
2007 study that had been in storage at −80 ◦C for 4–5 years, which included all 
children with concordant negative HIV RT or discordant HIV RT with negative HIV 
ELISA, and samples with initially discordant HIV RT results and undetectable HIV-
1 RNA PCR. HIV-infected was defined as a single positive HIV-1 RNA PCR > 400 
copies/ml; HIV uninfected was defined as a single negative undetectable HIV-1 
RNA PCR. The HIV prevalence was 7% amongst the mothers and 3.4% amongst the 
1602 enrolled children. The study did not collect data on maternal or infant cART 
although the authors state that since the study was done in 2006/2007 it is unlikely 
that many of the children in this age range would have been diagnosed with HIV 
infection and on cART. 
The performance of the HIV RTs used alone and in parallel for the exclusion of HIV 
infection in comparison to HIV NAAT was evaluated. The study found that all 
children (n=1526) with 2 negative HIV RTs were HIV negative by HIV NAAT and 
all children (n=46) with 2 positive HIV RTs were HIV positive by HIV NAAT. 
Overall, 2 negative HIV RTs performed in parallel had a NPV (95% CI) for HIV 
infection of 100% (99.7-100%), and a single negative RT had a NPV of 99.9% 
(99.6-100%) (Determine) and 99.5% (99-99.7%) (Capillus). Sensitivity and 
specificity were ≥99% and >98% respectively across all age brackets between ≥2 
months and <18 months. Sensitivity and specificity for a single HIV RT was 98.2% 
(90.4-99.7%) and 99% (98.4-99.4%) respectively for Determine, and 85.5% (73.8-
92.4%) and 99.6% (99.2-99.8%) respectively for Capillus. In summary, no infected 




discordant results occurred in <2% of those tested. This study highlighted the 
valuable role that HIV RTs can play in excluding HIV infection in children aged <18 
months with much lower cost and complexity than HIV NAAT.      
 
HIV RT on oral fluid in children 
 
Oral fluid samples may be tested for HIV antibodies and a number of assays have 
been developed for laboratory ELISA or HIV rapid testing. Oral fluid sampling is 
less invasive than blood sampling and may be more acceptable to parents whose 
infants are undergoing HIV screening. For healthcare workers less skill is required, 
there is lower risk of occupational exposure to HIV infection and it is less time-
consuming than blood sampling.  
 
OraQuick Advance Rapid HIV-1/2 Antibody Test (OraSure Technologies, 
Bethlehem, PA), an oral fluid rapid test, and OraSure, an oral fluid collection device 
that is licensed for use with the oral fluid Vironostika Microelisa system (Organon 
Teknika Corp., Durham, NC) have been found to have sensitivities between 93.3 and 
100% and specificities of 99.2 to 100% in adult studies.48,49 These two tests were 
evaluated in children 11 to 18 months of age for the detection of seroreversion as a 
means of excluding HIV infection in HIV-exposed children.50 Sensitivity was 87% 
(OraQuick) and 95% (OraSure) and specificity was 97% (OraQuick) and 93% 
(OraSure). However, both tests did show NPV of >99% and could potentially be 
used to detect seroreversion earlier than laboratory HIV ELISA.  
 
In a more recent study involving infants <6 months of age, OraQuick, OraSure, and 
another oral fluid antibody test (Calypte AWARE HIV-1/2 OMT Antibody Test 
(Calypte Biomedical Corporation, Portland, OR) achieved sensitivities <80% and the 
authors stated that oral fluid rapid tests cannot currently be recommended above 





RATIONALE FOR DOING THE STUDY 
 
Although previous and current South African NDOH guidelines for the management 
of HIV in children make provision for the use of HIV RTs to assess HIV-exposure in 
children <18 months of age, uncertainty about the interpretation of HIV RT results in 
children <18 months of age or lack of data validating the performance of HIV RTs in 
infants and young children result in the HIV PCR test frequently being the only HIV 
test used in children <18 months of age .52,53 It would be preferable for the same HIV 
RTs to be used for both HIV screening in infants and young children and HIV 
diagnosis in adults as this would reduce costs, training and complexity for public 
health programmes. This would also facilitate the incorporation of infants and young 
children into health care provider-initiated HIV counseling and testing (HCT) 
campaigns. In addition, HIV RTs that reliably and accurately detect seroreversion 
early but are also sensitive enough not to miss HIV-exposed, infected infants reduce 
the need for expensive HIV PCR tests and allow for same-day results. Based on 
previous studies, HIV RTs could potentially distinguish virtually all HIV-exposed 
uninfected from HIV-exposed infected infants from 8-10 months of age and possibly 
as early as 6-8 months of age. 42,43  
 
This study set out to evaluate the performance in children of HIV RTs currently in 
use in the South African public sector for both adult and paediatric HIV testing. The 
2009-2011 South African National Department of Health (NDOH) tender included 
the following HIV RTs: Advanced Quality One Step Anti HIV (1&2) (InTec 
Products Inc.); SD Bioline HIV 1/2 3.0 (Standard Diagnostics, Inc.); G. Ocean 
(additional details not available), First Response HIV 1-2.0 Card test (Premier 
Medical Corporation Ltd.), and Abbott Determine HIV-1/2 (Abbott Laboratories).  
 
Existing data indicate that not all HIV RTs perform equally well in HIV-exposed 
infants and children <18 months of age. Among the HIV RTs that have been 
evaluated using the laboratory HIV ELISA test as the standard for comparison, only 
the Determine RT has shown sensitivity for the detection of HIV exposure that meets 
the minimum requirement of 99% recommended by WHO for an HIV antibody 




low as 70%. 42,43 Since there are very few published studies, public health 
programmes have little evidence on which to base their choice of HIV RTs to be 
used in infancy and run the risk of under-diagnosing HIV-exposure leading to 
missed treatment opportunities for HIV-infected children. WHO has highlighted that 
assessing the performance of different HIV serological assays in infants and young 





























RATIONALE FOR SELECTING RED CROSS WAR MEMORIAL 
CHILDREN’S HOSPITAL, CAPE TOWN, WESTERN CAPE 
PROVINCE, SOUTH AFRICA AS ONE OF THE STUDY SITES 
In the South African public health sector, procurement of HIV RTs is via a national 
tender process with subsequent allocation to provinces. The specific HIV RTs 
allocated to provinces for screening and confirmation of HIV infection varies by 
province and does not take into account validation for paediatric testing.  
However, in June 2008, based on published scientific literature indicating higher 
sensitivity of the Determine RT for detection of HIV exposure in infants in 
comparison to other available HIV RTs, the Western Cape Province Department of 
Health introduced a new HIV testing algorithm for children. 43 According to the 
algorithm (Figure 1), children with unknown HIV status are screened using the 
Determine RT. If the Determine RT result is negative, the child is reported as sero-
negative. If the Determine RT result is positive, the specimen is tested with a second 
test. For children <18 months of age, the confirmatory test is the HIV PCR test and 
for children >18 months of age, the confirmatory test was the laboratory HIV ELISA 
test. 
Since 2008, all HIV testing at Red Cross War Memorial Children’s Hospital 
(RCWMCH), a paediatric tertiary referral hospital in Cape Town has been carried 
out in accordance with the Western Cape Province HIV testing algorithm. HIV 
testing takes place in the Haematology laboratory that is quality-accredited and 
managed by the National Health Laboratory Service (NHLS). In the routine HIV 
testing algorithm, testing is usually performed on EDTA blood samples. Ideally, 2 
EDTA microtainer tubes with ±500µl of blood in each tube are submitted to the 
laboratory but this is dependent on the volume of blood obtained by the clinician 
performing venesection on the child. The sample (first tube) undergoes 
centrifugation at 2500 revolutions per minute for 10 minutes. The Determine HIV 
RT is then performed on plasma according to the manufacturer’s instructions in the 




RT is reported as HIV-uninfected although the clinician is required to interpret the 
result in the context of infant feeding as described in Figures 1. In children who test 
positive with the Determine RT, the same sample or a second EDTA sample if 
available is forwarded to the virology laboratory at Groote Schuur Hospital (GSH) 
for the TNA PCR test (COBAS Ampliprep/COBAS TaqMan HIV-1 Qual test 
(Roche) if the child is <18 months of age or HIV ELISA test (Behring Enzygnost 
Anti HIV1/2 Plus laboratory ELISA) if the child is ≥18 months of age. The Behring 
Enzygnost Anti HIV1/2 Plus has a sensitivity of 100% and specificity of 99.3-100% 
in relation to comparable laboratory assays in studies on adult samples performed at 
four different centres in Europe, North America and Africa according to the 
manufacturers.54 Data on paediatric samples is not available.    
 
Between January and December 2010, approximately 5226 children <15 years of age 
underwent HIV rapid testing at RCWMCH (personal communication, RCWMCH 
NHLS laboratory). Table 6 summarises the results of children undergoing HIV 
testing at RCWMCH during 2010.  
 
The combination of a quality-assured laboratory infrastructure that implemented a 
standardised HIV testing algorithm together with relatively high numbers of children 
across all age categories undergoing HIV RT and HIV PCR testing suggested that 
RCWMCH represented a reliable, efficient and cost-effective location to undertake a 
study on the performance of HIV RTs in children. However, it was acknowledged at 
the outset that the duration of the study would depend on accessing adequate 
volumes of leftover blood samples in order to perform the HIV RTs being evaluated 
as well as adequate numbers of HIV-infected children to enable meaningful 
statistical analysis.   
 
At the same time as the Cape Town study was being performed, a similar study 
evaluating the same HIV RTs  on leftover whole blood samples from children 
undergoing HIV PCR or HIV viral load testing took place in the Department of 
Molecular Medicine and Haematology, Faculty of Health Sciences, University of 
Witwatersrand, Johannesburg, South Africa under supervision of Professor Gayle 




study. Combining the 2 study datasets into a single larger dataset allowed for a more 
powerful statistical analysis to be performed.  
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<18 mths of age 
• Pre-test counsel caregiver & obtain consent for HIV
testing 
Do Abbott Determine® rapid test on child 
Child is breastfeeding 
• Continue co-trimoxazole
• Repeat HIV testing according to
this algorithm ≥6 wks after
stopping breastfeeding or if child
develops clinical features of HIV
infection during period of
breastfeeding
NO breastfeeding in last 6 
weeks 
Child is HIV-uninfected 
• Post-test counsel caregiver
• Stop co-trimoxazole
PCR test is positive 
Child is HIV-infected 
• Post-test counsel caregiver
• Manage further or refer to HIV
clinic
• Encourage HIV testing for
parents & siblings
PCR test is negative 
 (≥6 wks of age) 
Do HIV DNA PCR test on child 
• Start co-trimoxazole prophylaxis if ≥6 wks of age
• Arrange follow-up date for test results
Do Abbott Determine® rapid test on child 
• If mother is known to be HIV-infected & child is <9 mths of
age, skip rapid test & proceed directly to PCR test
Do confirmatory HIV ELISA test on 
child 
• Start co-trimoxazole prophylaxis
Positive rapid test & ELISA test 
Child is HIV-infected 
• Post-test counsel caregiver &/or child
• Manage further or refer to HIV clinic
• Encourage HIV testing for parents &
siblings
Child is breastfeeding 
• Repeat HIV testing according
   to this algorithm ≥6 wks after
stopping breastfeeding or if child
develops clinical features of  HIV
infection during period of
breastfeeding
NO breastfeeding in last 6 weeks 
Child is HIV-uninfected 
• Post-test counsel caregiver &/or
child
Child with unknown HIV status 
Rapid test is positive Rapid test is negative Rapid test is negative Rapid test is positive 
Figure 1. HIV testing algorithm, Western Cape (2008) 
>18 mths of age
• Pre-test counsel caregiver and/or child & obtain consent for HIV testing
Children >12 yrs of age can consent for their own testing 
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2 (1.0) 10 N/A 6 
(60.0) 
0 
Total 4242 511 3641 90 1253 194 1056 3 
 
The number of HIV PCR tests performed exceeds the number of positive HIV RTs as children who were known 
to be HIV-exposed at the time of testing frequently have an HIV PCR test without an HIV RT being performed 
















AIM OF THE STUDY 
 
The aim of this study was to evaluate the diagnostic accuracy of HIV RTs in use in 
2011 for HIV testing in South Africa. In children <18 months of age, HIV RTs were 
evaluated for:   
1. detection and exclusion of HIV exposure  
2. detection of seroreversion 
3. detection of HIV-exposed and -infected children  
 
In children aged 18 months – <15 years, HIV RTs will be evaluated for: 
4. diagnosis and exclusion of HIV infection  
  
The standard for comparison of HIV RT results in this study wasthe Behring 
Enzygnost Anti HIV1/2 Plus laboratory ELISA test and the Total Nucleic Acid 
(TNA) PCR test (COBAS Ampliprep/COBAS TaqMan HIV-1 Qual test (Roche).  
 
SPECIFIC OBJECTIVES OF THE STUDY 
 
1. To determine the sensitivity, specificity, positive and negative likelihood 
ratios of each of the HIV RTs in comparison to the Behring Enzygnost Anti 
HIV1/2 Plus laboratory ELISA test for detection and exclusion of HIV 
exposure in children <18 months of age. 
2. To determine the ability of the each of the HIV RTs to detect seroreversion in 
comparison to the Behring Enzygnost Anti HIV1/2 Plus laboratory ELISA 
test in children <18 months of age 
3. To determine the ability of each of the HIV RTs to detect HIV-exposed and –
infected children <18 months of age in comparison to the Behring Enzygnost 
Anti HIV1/2 Plus laboratory ELISA test and TNA PCR test (COBAS 
Ampliprep/COBAS TaqMan HIV-1 Qual test (Roche).  
4. To determine the sensitivity, specificity, positive and negative likelihood 
ratios of each of the HIV RTs for detection and exclusion of HIV infection in 
comparison to the Behring Enzygnost Anti HIV1/2 Plus laboratory ELISA 
test in children ≥18 months - <15 years of age.   




MATERIALS AND METHODS 
 
Study design and setting 
 
A prospective, cross-sectional laboratory study was conducted over a 3-year period 
between June 2011 and June 2014 in the Haematology laboratory of the NHLS at 
RCWMCH in Cape Town and from June 2012 – June 2014 in the Department of 
Molecular Medicine and Haematology, University of Witwatersrand, Johannesburg  
 
Eligibility for inclusion in the study was the availability of leftover EDTA whole 
blood sample from any child <15 years of age whose blood was submitted to the 
laboratory for HIV testing. Blood samples that were older than 24 hours from time of 
arrival at the laboratory were not eligible for inclusion in the study.  
 
Figures 2 and 3 show the study HIV testing algorithms for children <18 months of 
age and children ≥18 months of age respectively. The study algorithms incorporate 
both the routine HIV testing algorithm (Figure 1) used at RCWMCH and additional 
study-specific testing procedures in order to facilitate the recruitment of leftover 
blood sample for the study. A study HIV ELISA test was performed on all samples 
included in the study that did not have an HIV ELISA test performed in the routine 
HIV testing algorithm (including children <18 months of age with positive routine 
Determine RT results and children of all ages with negative routine Determine RT 
results) to act as the reference standard for that child against which to assess the 
performance of the different HIV RTs (index tests).  
 
The 2009-2011 NDOH tender included the following HIV RTs: Advanced Quality 
One Step Anti HIV (1&2) (InTec Products Inc.); SD Bioline HIV 1/2 3.0 (Standard 
Diagnostics, Inc.); G. Ocean (additional details not available), First Response HIV 1-
2.0 Card test (Premier Medical Corporation Ltd.), and Abbott Determine HIV-1/2 
(Abbott Laboratories). The study was able to obtain donated stock from the NDOH 
of Advanced Quality, SD Bioline and Determine RTs but was unable to obtain 
donated or purchased stock of G. Ocean or First Response RTs. The Reveal Rapid 
HIV Antibody Test (MedMira Laboratories Inc.) and Insti HIV-1 RT (BioLytical 




Laboratories, British Columbia, Canada) were purchased using study funding. The 
Insti HIV-1 RT was included in the study as it had been evaluated in 2 previous local 
studies and warranted further investigation due to its good performance and short 
testing time of 1 minute. During the course of the study, the SD Bioline RT was 
officially withdrawn from use in the NHLS and replaced with the Abon HIV Tri Line 
1/2/0 RT (Abon Biopharm (Hangzhou) Co. Ltd.). The Abon RT was therefore 
included in this study following the replacement of SD Bioline.  
 
When the amount of available EDTA whole blood sample was insufficient for both 
the study HIV ELISA test and the study HIV RTs to be performed, suitable leftover 
plasma or serum from biochemical tests submitted from the same child and taken at 
the same time as the sample for HIV testing was used for the study HIV ELISA test 
(but not for the HIV RTs) at the Cape Town study site.  
 
Although the Determine RT is routinely performed on plasma at RCWMCH, many 
HIV testing facilities do not have the equipment to separate plasma and therefore for 
reasons of generalizability this study focussed on the performance of the Determine 
RT and the other HIV RTs on whole blood. The study design did not accommodate 
the assessment of HIV RTs performed on capillary blood samples obtained directly 
from finger-prick samples. Remaining whole blood sample was used for dried blood 
spots for later HIV TNA PCR testing if required.  
 
At both study sites, a trained laboratory technologist with experience in HIV testing 
performed all study-related laboratory procedures and followed a standard operating 
procedure. The laboratory technologist performing the HIV RTs was blinded to the 
result of the HIV ELISA test and HIV PCR test at the time of performing the HIV 
RTs and the laboratory technologist performing the HIV ELISA or HIV PCR tests 
was blinded to the results of the HIV RTs. All HIV RTs were performed according to 
the manufacturer’s instructions as stated in each package insert. 55-60 Weakly positive 
HIV RT results were reported as positive. Since the available volume of EDTA 
whole blood varied, HIV RTs were performed in the following order of priority: 
Insti, Reveal, SD Bioline / Abon, Advanced Quality, Determine. Depending on the 
volume of sample available, all or some of the HIV RTs were performed for each 
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patient. Sample volumes were usually inadequate to allow for routine repeating of 
HIV RT and/or HIV ELISA tests when results were discordant. Known negative and 
positive controls for HIV antibodies were obtained from the National Institute for 
Communicable Diseases (NICD), aliquoted and frozen. All the HIV RTs were tested 
at the beginning of each week with the known positive and negative controls and 
whenever a new batch of a particular HIV RT was used, to check the integrity of the 
HIV RT kits.  
The study algorithms and HIV RT procedures did not interfere with the reporting of 
routine Determine RT, HIV ELISA or HIV PCR results to the clinician and the 
results of study-specific tests were not released to clinicians. 
A formal sample size calculation was not undertaken prior to starting the study as it 
was decided that the initial study budget could accommodate a convenience sample 
collected over approximately one year with review of progress with respect to the 
rate of recruitment of samples.  
The cost of the tests used in the routine HIV testing algorithm (Determine RT and 
HIV PCR tests for HIV-exposed children <18 months of age and HIV ELISA tests 
for children ≥18 months of age who test positive with Determine RT) at RCWMCH 
was covered by the Western Cape Province Department of Health. Funding for the 
remaining costs of the study including purchasing HIV RTs (some were donated by 
the NDOH), laboratory equipment, and employment of a laboratory technologist was 
from the United Children’s Fund (UNICEF) and University of Witwatersrand 
(WITS) Health Consortium Pty Ltd. The study was not adequately funded to perform 
HIV PCR testing on children who tested negative with the routine Determine RT or 
negative with the HIV ELISA test at the RCWMCH study site.  






For the purposes of this study, the following definitions are used: 
1. HIV exposure was defined as a positive laboratory HIV ELISA test (Behring 
Enzygnost Anti HIV1/2 Plus) result in a child <18 months of age  
2. HIV infection 
a. in a child <18 months of age was defined as a positive HIV PCR test 
result (COBAS Ampliprep/COBAS TaqMan HIV-1 Qual test (Roche)    
b. in a child ≥18 months of age was defined as a positive Determine rapid 
test result followed by a positive laboratory HIV ELISA test (Behring 
Enzygnost Anti HIV1/2 Plus) result.  
3. An equivocal laboratory HIV ELISA test was one that did not meet the 
laboratory criteria for a positive or negative result (the optical density is 10% 
above or below the cut-off value for the test). 
4. An invalid laboratory HIV ELISA test or HIV rapid test was one in which no 
result is obtained as a result of insufficient sample volume, failure of the 
Control strip to appear, or failure of the blood sample or buffer to move along 




Study data comprised the date of birth of each child undergoing HIV testing, the date 
of blood sampling and qualitative results of all HIV RTs, HIV ELISA and HIV PCR 
tests. Study data was entered into an Excel spreadsheet by the study laboratory 
technologist using a laboratory number and study number and was accessible only to 
the study technologist and investigator. The data was regularly reviewed by the 













The dataset for analysis comprises data from the Cape Town (CT) and Johannesburg 
(Jhb) study sites. Children with pre-defined equivocal or invalid HIV ELISA, HIV 
PCR or HIV RT results were excluded from the analyses and only children with a 
valid result (positive or negative) are included.  
 
The laboratory HIV ELISA test results were used to calculate the prevalence of HIV 
exposure among children <18 months of age (by different age categories) and the 
prevalence of HIV infection among children ≥18 months of age. The HIV PCR test 
results were used to calculate the prevalence of HIV infection among children <18 
months of age. The laboratory HIV ELISA test result was the reference standard for 
HIV exposure (in children <18 months of age) and HIV infection (in children ≥18 
months of age) against which the sensitivity, specificity, and positive and negative 
likelihood ratios of each of the 6 HIV RTs (the index tests) are calculated.  
 
Sensitivity (true-positive results / [true-positive + false-negative results]) refers to the 
proportion of children with the target condition (HIV exposure for children <18 
months of age or HIV infection for children ≥18 months of age) who tested positive 
with the index test (HIV RT). Specificity (true-negative / [true-negative + false-
positive results]) refers to the proportion of children without the target condition 
(HIV exposure for children <18 months of age or HIV infection for children ≥18 
months of age) who tested negative with the index test (HIV RT). Sensitivity and 
specificity values across different age categories for each of the 6 HIV RTs were 
calculated with 95% CI using the Wilson score method (Confidence interval 
calculator, Physiotherapy Evidence Database (PED), version 24 March 2011, 
available at www.pedro.org.au/wp-content/uploads/CIcalculator.xls). 
 
Since the prevalence of HIV exposure and infection varied across each age category, 
calculation of positive and negative predictive values was precluded. Positive and 
negative likelihood ratios (LR+ and LR-) were used instead. The likelihood ratio of a 
positive test provides a measure of how much more likely a positive test result is in 
someone with the target condition as compared with someone without the target 




condition. A LR+ >1 indicates an increased probability that the target condition is 
present and an LR- <1 indicates a decreased probability that the target condition is 
present. LR+ and LR- values of >10 and <0.1 respectively indicate a very high or 
very low likelihood of the target condition being present. In this study, a positive 
likelihood ratio of >10 strongly predicted HIV exposure (in the analysis of HIV RT 
in comparison to laboratory HIV ELISA for detection of HIV exposure in children 
<18 months of age) or HIV infection (in the analysis of HIV RT in comparison to 
HIV ELISA for diagnosis of HIV infection in children ≥18 months of age). 
Similarly, a negative likelihood ratio of <0.1 strongly predicted exclusion of HIV 
exposure or infection. 61 
 
The laboratory HIV ELISA and HIV PCR test results were also used to calculate 
seroreversion rates for the different HIV RTs across different age categories and the 
ability of each of the HIV RTs to detect HIV-exposed and infected children <18 




The study protocol was approved by the Departmental Research Committee of the 
Department of Paediatrics and Child Health, University of Cape Town and the 
Human Research Ethics Committee of the University of Cape Town (HREC REF 
218/2011). Permission to conduct the study at RCWMCH was obtained from the 
hospital research committee. The Johannesburg study site obtained approval to 
conduct the study from the University of the Witwatersrand Ethics Committee  
(Protocol approval M09-06-88). 
 




Figure 2. HIV testing algorithm for children <18 months of age 
(incorporating routine laboratory and study technologist roles)  
        
Child with unknown HIV status 
 
EDTA blood submitted to laboratory (ideally 2 microtainer tubes with ±500µl in each tube) 
     
 
       First tube      Second tube or other suitable EDTA sample on child  
  
1. Routine laboratory: centrifuge & separate sample (±150µl plasma)      1. Study technologist: perform HIV RTs on whole blood: 
2. Study technologist: obtain plasma (±100µl) & submit to GSH for          a. INSTI (50µl) 
HIV Behring Enzygnost Anti HIV 1/2 Plus ELISA (reference standard)        b. Reveal (1 drop)      
3.   Routine laboratory: perform Determine HIV-1/2 rapid test on plasma (50µl)       c. SD Bioline (20µl) / Abon (2 drops)  
                    d. Advance Quality (10µl)                    
                      e. Determine (50µl) 
                         
    2. Study technologist: if sufficient whole blood leftover,   
    make and store Dried Blood Spots (±300ul) for later  
                  HIV tests if required 
     Negative     Positive         
 
COBAS Ampliprep/COBAS TaqMan HIV-1 Qual test 
       
            Negative  Positive  
 
         HIV-infected 
 
 Child is ≥6 weeks of age AND no breastfeeding in last 6 weeks 
   
HIV-uninfected 
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Figure 3. Study HIV testing algorithm for children ≥18 months of age 
(incorporating routine laboratory and study technologist roles) 
Child with unknown HIV status 
EDTA blood submitted to laboratory (ideally 2 microtainer tubes with ±500µl in each tube) 
First tube Second tube or other suitable EDTA sample on child 
1. Routine laboratory: centrifuge & separate sample (±150µl plasma) 1. Study technologist: perform HIV RTs on whole blood:
2. Routine laboratory: perform Determine HIV-1/2 rapid test on plasma (50µl) a. INSTI (50µl)
b. Reveal (1 drop)
c. SD Bioline (20µl) / Abon (2 drops)
d. Advance Quality (10µl)
e. Determine (50µl)
2. Study technologist: if sufficient whole blood leftover,
make and store Dried Blood Spots (±300ul) for later
HIV tests if required
      Negative Positive 
HIV-uninfected  HIV Behring Enzygnost Anti HIV 1/2 Plus ELISA 
If no breastfeeding 
in last 6 weeks         Negative  Positive 
       HIV-infected 
Study technologist: obtain plasma  
(±100µl) & submit to GSH for  Further tests 
HIV Behring Enzygnost Anti HIV required in order 
1/2 Plus ELISA (reference standard)   to establish HIV 
status of child 






The flow of study participants in relation to the study tests performed is shown in 
Figure 4. A total of 1173 children <15 years of age had laboratory HIV ELISA 
testing done, 754 at the CT study site and 419 at the Jhb study site. There were 4 
(0.3%) children (all <9 months of age) with an equivocal HIV ELISA test result (all 
at the CT study site), and 10 (0.9%) children (all at the Jhb study site) in whom the 
HIV ELISA test was invalid. The 14 children with equivocal or invalid HIV ELISA 
tests were excluded from the statistical analysis. In these 14 children, the results of 
the HIV RTs varied but all had a negative HIV PCR test. The study population with 
a valid HIV ELISA test result included in the statistical analysis comprised 1159 
children of which 896 were <18 months of age (Table 7) and 263 were ≥18 months 
of age (Table 8). Among children with a valid HIV ELISA result, the highest number 
of tests (353/896, 39.4%) was performed in children <3 months of age and the 
lowest number (54/896, 6.0%) in children 15-<18 months of age.  Among the 896 
children <18 months of age with a valid HIV ELISA result, a positive result was 
obtained in 488/896 giving an overall HIV exposure rate of 54.5% ranging from 
69.1% (125/181) in the 3-<6 months age group to 13.2% (10/76) in the 12-<15 
months age group. Among the 263 children ≥18 months of age with a valid HIV 
ELISA result (262 from the CT site and 1 from the Jhb site) the HIV prevalence rate 
was 4.9% (13/263) and there were no equivocal results or invalid HIV ELISA tests. 
 
A total of 5768 HIV RTs were performed on whole blood, 3673 at the CT study site 
and 2095 at the Jhb study site. There were 32 HIV RTs (31 Reveal and 1 Abon RT) 
with invalid results (all at the Jhb study site) and these were excluded from the 
statistical analysis. A total of 5736 HIV RTs were included in the statistical analysis. 
Among the 896 children <18 months of age with a valid HIV ELISA result, a total of 
4446 valid HIV RT results were obtained ranging from 1752 HIV RTs in the <3 
month age group to 266 HIV RTs in the 15-<18 month age group (Table 9). Among 
the 263 children ≥18 months of age with a valid HIV ELISA result, a total of 1290 
HIV RTs were performed (Table 10). The wide variation in the number of children 
undergoing testing with each of the RTs is because the volume of available blood 
sample for each child varied and because HIV RTs were performed in a protocol-




defined sequence of priority. In addition, during the course of the study, the SD 
Bioline RT was withdrawn from use in the Department of Health and was replaced 
with the Abon RT.   
 
Valid HIV PCR test results were available for 78.7% (705/896) of the children <18 
months of age, 298 from the CT study site and 408 from the Jhb study site. One child 
(CT study site) tested positive with the HIV ELISA test and all the HIV RTs but the 
HIV PCR test result was equivocal. This child was excluded from the analysis of 
HIV RT performance in relation to detecting HIV PCR positive children. The HIV 
PCR test was repeated 2 days later (outside of the study) and the result was 
equivocal again. Unfortunately, the child was subsequently lost to follow-up. There 
was one child in the 15-<18-month age category (Jhb site) in whom the HIV ELISA 
test was negative but all the HIV RTs (except Reveal) were positive and the HIV 
PCR test was positive. There was insufficient sample available to repeat the tests and 
this child was excluded from the analysis of HIV RT performance for detection of 
HIV exposure and HIV infection in view of the discordant results. Among children 
<18 months of age with both a valid HIV ELISA and a valid HIV PCR result, the 
overall HIV prevalence was 9.6% (68/705) ranging from 41.9% (13/31) in the 15-
<18 month age group to 5.7% (17/299) in the <3 month age group (Table 7).  
 
Children <18 months of age 
 
Diagnostic performance of HIV RTs for detection and exclusion of HIV exposure 
 
The sensitivity (95% CI) and positive likelihood ratio (LR+) of the 6 HIV RTs for 
detection of HIV exposure (HIV ELISA+) in children <18 months of age is shown in 
Table 11. The overall sensitivity values ranged from 38.7% (Reveal) to 94.7% 
(Determine). In children <3 months of age, the sensitivity values ranged from 56.3% 
(Reveal) to 98.7% (Determine) with all HIV RTs except Reveal detecting between 
94.9 – 98.7% of HIV-exposed infants. Positive likelihood ratios were all >10 
indicating strong prediction of correctly identifying HIV exposure. Positive 
likelihood ratios could not be calculated for 3 HIV RTs (Reveal, Abon, SD Bioline) 
that had 100% specificity for detection of HIV exposure (no false-positive results).  





In a subset of children at the CT study site, the Determine RT was also performed on 
plasma in the routine HIV testing laboratory (Figures 2 and 3). The sensitivity of the 
Determine RT performed on plasma in children <18 months of age was higher than 
the sensitivity on whole blood (98.7 versus 94.7%) but the 95% CIs were 
overlapping (Table 11). In children <3 months of age, the sensitivity of the 
Determine RT was similar on plasma compared with whole blood (96.6 versus 
98.7%).  
 
The specificity (95% CI) and negative likelihood ratio (LR-) of each of the 6 HIV 
RTs for excluding HIV exposure was assessed in the 408 HIV ELISA negative 
children <18 months of age and is shown in Table 12. The Insti, Reveal, SD Bioline 
and Advanced Quality RTs all showed specificities >98% with 3, 0, 1, and 2 false 
positive results respectively. Six Abon and 27 Determine RT false-positive results 
were obtained with specificities of 97.0% (95% CI 93.6-98.6) and 93.1% (95% CI 
90.1-95.2) respectively but both these HIV RTs had negative likelihood ratios of 0.1. 
In children <3 months of age, the specificities of all the HIV RTs were >98% except 
Determine for which 3 false positive results were obtained with a specificity of 
97.4% (95% CI 92.6-99.1).  
 
The specificity of the Determine RT performed on plasma in a subset of children at 
the CT study site was similar to that on whole blood for children <18 months of age 
and children <3 months of age (92.6 versus 93.1% and 98.1 versus 97.4% 
respectively) as shown in Table 12.  
 
Diagnostic performance of HIV RTs for detection of seroreversion 
 
The performance of the 6 HIV RTs in detecting seroreversion was assessed as the 
percentage of negative HIV RT results in HIV-exposed and uninfected (HIV 
ELISA+, HIV PCR-) children <18 months of age (Table 13). Among infants <4 
months of age, 5 of the 6 HIV RTs had seroreversion rates of <15%. The Reveal 
HIV RT showed seroreversion rates of up to 64% in infants aged between 2 and 4 
months of age but this is likely to be related to the low sensitivity of this RT. 




Although much higher rates of seroreversion were detected among children >8 
months of age for most of the HIV RTs, a relatively low number of samples in 
children between 8 and 18 months of age limited the value of this analysis. The 
Determine RT showed the lowest rate of seroreversion in comparison to the other 
HIV RTs across all the age categories in keeping with the high sensitivity of this RT.              
 
Diagnostic performance of HIV RTs for detection of HIV exposed and –infected 
children 
 
The performance of the 6 HIV RTs in detecting HIV-infected (HIV PCR+) children 
is shown in Table 14. All of the HIV RTs except the Reveal RT detected 95-100% of 
HIV-infected children with the Abon, Advanced Quality and Determine RTs 
detecting 100% of HIV-infected children <18 months of age. The Reveal RT missed 
27/65 (41.5%) HIV-infected children mostly <8 months of age and 16-18 months of 
age. The SD Bioline RT missed 1 child of 11-12 months of age out of 22 HIV-
infected children (4.5%) and the Insti RT missed 1 child of 3-4 months of age out of 
68 HIV-infected children (1.5%).  
 
In the 8-10 month age category during which time the WHO recommends routine 
screening for HIV infection using HIV RTs, no HIV-infected children were missed 
by any of the HIV RTs however the number of HIV-infected children (HIV PCR+) 
was very low. Under 3 months of age, only the Reveal RT was unable to detect 
100% of HIV-infected children. 
 
Children ≥18 months of age  
 
Diagnostic performance of HIV RTs for detection and exclusion of HIV infection 
 
The sensitivity values ranged from 69.2% (9/13) with the Reveal RT to 100% with 
the Abon (4/4), SD Bioline (8/8) and Determine (13/13) RTs respectively (Table 15). 
Confidence intervals were wide owing to the small number of HIV ELISA positive 
children ≥18 months of age. The specificity of the 6 HIV RTs for excluding HIV 
infection was 100% (Table 16). The positive and negative likelihood ratios indicated 




that these 6 HIV RTs were strongly able to predict or exclude HIV infection in this 
age category. 
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Figure 4. Flow of study participants in relation to study tests performed 
HIV ELISA test results excluded (n=14): 
1. Equivocal laboratory HIV ELISA test result (n=4, all at CT study site)
2. Invalid laboratory HIV ELISA test (n=10, all at Jhb study site)
Participants with a valid laboratory HIV ELISA test result (n=1159) 
1. <18 months of age (n = 896)
2. ≥18 months of age (n = 263)
Total number of HIV Rapid Tests (RTs) performed (n = 5768) 
1. CT study site (n = 3673)
2. Jhb study site (n = 2095)
Cape Town (CT) study site 
Potentially eligible participants: 
Children (<15 years of age) undergoing routine HIV testing 
from June 2011 –June 2014 
Johannesburg (Jhb) study site 
Potentially eligible participants: 
Children (<15 years of age) undergoing HIV PCR or HIV VL testing 
from June 2012 – June 2014   
Eligible participants with suitable leftover sample available and laboratory HIV ELISA testing (reference standard) was performed (n = 1173) 
1. CT study site (n = 754)
2. Jhb study site (n = 419)
Total number of participants <18 months of 
age with a valid laboratory HIV ELISA test 
result in whom HIV PCR testing was 
performed (n = 706) 
1. CT study site (n = 298)
2. Jhb study site (n = 408)
HIV RT results excluded ((n = 32): 
1. Invalid HIV RT result (n = 32, all at Jhb study site)
Total number of valid HIV RT results included in the analysis (n = 5736): 
1. Valid HIV RT results in children <18 months of age (n = 4446)
2. Valid HIV RT results in children ≥18 months of age (n = 1290)
HIV PCR test results excluded (n = 1): 
1. Equivocal HIV PCR test result (n = 1,
at CT study site) 
Participants with a valid HIV PCR test result 
(n = 705) 




Table 7. Description of study cohort: children <18 months of age 
 









































HIV PCR+ / 
(HIV PCR+ 
plus HIV PCR-) 
(%) 
Equivocal 






0-<3 353 234 119 234/353 (66.3) 1 3 299 17 281 17/299 (5.7) 1 54 
3-<6 181 125 56 125/181 (69.1) 2 5 154 17 135 17/154 (11.0) 0 29 
6-<9 142 83 59 83/142 (58.5) 1 0 116 11 104 11/116 (9.5) 0 27 
9-<12 90 24 66 24/90 (26.7) 0 1 59 7 52 7/59 (11.9) 0 31 
12-<15 76 10 66 10/76 (13.2) 0 0 50 3 47 3/50 (6.0) 0 26 
15-<18 54 12 42 12/54 (22.2) 0 1 31 13 18 13/31 (41.9) 0 23 
Total 896 488 408 488/896 (54.5) 4 10 705 68 637 68/705 (9.6) 1 190 
 mo = months, ELISA = Enzyme Linked Immunosorbent Assay, PCR = Polymerase Chain Reaction 
  
 




















HIV ELISA+ / 
(HIV ELISA+ plus 
HIV ELISA-) (%) 
≥18 263 13 250 0 13/263 (4.9) 
   mo = months, ELISA = Enzyme Linked Immunosorbent Assay 
 




Table 9. Spectrum of HIV rapid tests (RTs) performed in children <18 months of age 














mo = months, ELISA = Enzyme Linked Immunosorbent Assay 
 
 














































<3 353 353 336 203 179 342 339 1752 
≥3-<6 181 181 175 108 86 178 173 901 
≥6-<9 142 142 138 91 57 141 138 707 
≥9-<12 90 90 90 45 50 89 87 451 
≥12-<15 76 76 72 46 35 71 69 369 
≥15-<18 54 54 53 26 25 54 54 266 
Total 
<18 
896 896 864 519 432 875 860 4446 














≥18 263 263 263 24 215 263 262 1290 





Table 11. Sensitivity (95% confidence interval [CI]) and positive likelihood 
ratio (LR+) of each HIV rapid test (HIV RT) for detection of HIV exposure 




























mo = months, ELISA = Enzyme Linked Immunosorbent Assay 


























95% CI LR+ 
<18 mo of age      
Insti 488 355 72.8 68.6-76.5 98.9 
Reveal 468 181 38.7 34.4-43.2 - 
Abon 319 275 86.2 82.0-89.6 28.7 
SD Bioline 202 171 84.7 79.0-89.0 194.7 
Advanced 
Quality 
475 379 79.8 76.0-83.2 159.6 
Determine  
(whole blood) 
469 444 94.7 92.3-96.4 13.7 
Determine 
(plasma)# 
75 74 98.7 92.8-99.8 13.4 
<3 mo of age      
Insti 234 222 94.9 91.3-97.0 112.9 
Reveal 222 125 56.3 49.7-62.7 - 
Abon 137 134 97.8 93.8-99.3 - 
SD Bioline 110 107 97.3 92.3-99.1 - 
Advanced 
Quality 
226 222 98.2 95.5-99.3 113.9 
 Determine 
(whole blood) 
225 222 98.7 96.2-99.6 37.5 
Determine 
(plasma)# 
29 28 96.6 82.8-99.4 51.2 
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Table 12. Specificity (95% confidence interval [CI]) and negative likelihood  
ratio (LR-) of each HIV rapid test (HIV RT) for excluding HIV exposure (HIV 
ELISA-) in children <18 months of age 
M 
mo = months, ELISA = Enzyme Linked Immunosorbent Assay 






Specificity 95% CI LR- 
<18 mo of age 
Insti 408 3 99.3 97.9-99.8 0.3 
Reveal 396 0 100 99.0-100 0.6 
Abon 200 6 97.0 93.6-98.6 0.1 
SD Bioline 230 1 99.6 97.6-99.9 0.2 
Advanced Quality 400 2 99.5 98.2-99.9 0.2 
Determine  
(whole blood) 
391 27 93.1 90.1-95.2 0.1 
Determine 
(plasma)# 
190 14 92.6 88.0-95.6 0 
<3 mo of age 
Insti 119 1 99.2 95.4-99.9 0.1 
Reveal 114 0 100 96.7-100 0.4 
Abon 66 0 100 94.5-100 0 
SD Bioline 69 0 100 94.7-100 0 
Advanced Quality 116 1 99.1 95.3-99.9 0 
Determine  
(whole blood) 
114 3 97.4 92.6-99.1 0 
Determine 
(plasma)# 
53 1 98.1 90.1-99.7 0 
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Table 13. Performance of each HIV rapid test (HIV RT) in detecting seroreversion (SR) in HIV-exposed and –uninfected (HIV ELISA+ HIV 
PCR-) children <18 months of age  
Age 
(mo) 




























<2 6/158 3.8 57/148 38.5 3/101 3.0 3/73 4.1 4/154 2.6 3/153 2.0 
2-<4 14/100 14.0 62/96 64.6 1/61 1.6 0/46 0 4/95 4.2 0/93 0 
4-<6 35/61 57.4 53/60 88.3 1/39 2.6 5/28 17.9 15/61 24.6 0/60 0 
6-<8 45/58 77.6 54/57 94.7 16/41 39.0 11/20 55.0 44/58 75.9 6/56 10.7 
8-<10 17/17 100 15/16 93.8 11/13 84.6 7/7 100 16/17 94.1 7/17 41.2 
10-<12 8/9 88.9 8/9 88.9 8/9 88.9 3/3 100 7/8 87.5 6/8 75.0 
12-<18 3/6 50.0 5/6 83.3 3/6 50.0 6/6 100 3/6 50.0 3/6 50.0 
mo = months, ELISA = Enzyme Linked Immunosorbent Assay, PCR = Polymerase Chain Reaction 
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Table 14. Performance of each HIV rapid test (HIV RT) in detecting  
HIV-infected (HIV PCR+) children <18 months of age (HIV PCR+, HIV RT+) 








% HIV PCR+ 
detected by  
HIV RT alone 
       <18 mo of age 
Insti 68 67 1 98.5 
Reveal 65 38 27 58.5 
Abon 41 41 0 100 
SD Bioline 22 21 1 95.5 
Advanced Quality 65 65 0 100 
Determine 65 65 0 100 
8-10 mo of age
Insti 3 3 0 100 
Reveal 3 3 0 100 
Abon 1 1 0 100 
SD Bioline 2 2 0 100 
Advanced Quality 3 3 0 100 
Determine 3 3 0 100 
<3 mo of age 
Insti 17 17 0 100 
Reveal 16 10 6 62.5 
Abon 6 6 0 100 
SD Bioline 7 7 0 100 
Advanced Quality 16 16 0 100 
Determine 16 16 0 100 





Table 15. Sensitivity (95% confidence interval [CI]) and positive likelihood ratio 
(LR+) of each HIV rapid test (HIV RT) for diagnosis of HIV infection (HIV ELISA+) 














Table 16. Specificity (95% confidence interval [CI]) and negative likelihood ration 
(LR-) of each HIV rapid test (HIV RT) for excluding HIV infection (HIV ELISA-) in 

















Sensitivity 95% CI LR+ 
Insti 13 12 92.3 66.7-98.6 92.3 
Reveal 13 9 69.2 42.4-87.3 69.2 
Abon 4 4 100 51.0-100 100 
SD Bioline 8 8 100 67.6-100 100 
Advanced Quality 13 12 92.3 66.7-98.6 92.3 






Specificity 95% CI LR- 
Insti 250 0 100 98.5-100 0.1 
Reveal 250 0 100 98.5-100 0.1 
Abon 20 0 100 83.9-100 0 
SD Bioline 207 0 100 98.2-100 0 
Advanced Quality 250 0 100 98.5-100 0.1 
Determine 249 0 100 98.5-100 0 
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DISCUSSION 
The WHO recommendations on the diagnosis of HIV infection in infants and 
children incorporate the use of HIV antibody detection assays for two main roles. 
Firstly, as a screening assay to determine HIV exposure in children <18 months of 
age, and secondly, for the diagnosis of HIV infection in children ≥18 months of age.  
The 2010 WHO guidelines recommend HIV antibody screening of infants with 
uncertain HIV exposure at or around birth, at the first postnatal visit (4-6 weeks of 
age) or other child health visit, at around 9 months of age, and in infants with signs 
or symptoms suggestive of HIV infection. For children ≥18 months of age with 
suspected HIV infection or HIV exposure, the guidelines strongly recommend that 
HIV antibody testing should be performed according to the standard diagnostic HIV 
testing algorithm used in adults. The guidelines also make provision for using HIV 
antibody detection assays in combination with a clinical algorithm for presumptive 
diagnosis of HIV infection in children <18 months of age in settings where testing 
with HIV viral detection assays is not available. 9  
These guidelines strongly recommended that HIV antibody detection assays used for 
clinical diagnostic testing (either screening or diagnostic testing) should have a 
minimum sensitivity of 99% and specificity of 98% under quality-assured, 
standardised and validated laboratory conditions but acknowledged only moderate 
quality of evidence available to support this recommendation. 9 Recent WHO HIV 
testing guidelines (2015) emphasise the important role of virological testing in HIV-
exposed infants from 4-6 weeks of age in order to rapidly identify HIV-infected 
infants who can start cART and also highlight that a negative HIV antibody test 
(including rapid tests) in an infant does not completely rule out HIV exposure and 
infection, especially between 4-18 months of age as a result of reduced sensitivity 
during seroconversion when HIV infection is acquired postpartum through 
breastfeeding. As with the 2010 guidelines, HIV antibody testing is still strongly 
recommended at 9 months of age for HIV exposed infants whose virological tests are 
negative at 4-6 weeks of age although the quality of evidence for this 
recommendation is acknowledged as being low. 62 
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This study evaluated the diagnostic accuracy of 6 HIV RTs in children <15 years of 
age using whole blood. In order to maximize the completeness and transparency of 
information provided in reporting this study, the Standards for Reporting Diagnostic 
Accuracy (STARD) 2015 checklist of 30 essential items has been incorporated 
(Appendix 4). 63 This appendix shows that a concerted effort was made to include as 
many of the STARD checklist items as possible into the study design, analysis, and 
structure and content of this report.  
Children <18 months of age 
None of the 6 HIV RTs evaluated achieved an overall sensitivity of ≥99% in 
comparison to laboratory HIV ELISA testing for the detection of HIV exposure 
among all children <18 months of age. The Determine RT was closest to attaining 
the WHO standard with overall sensitivity of 94.7% (95% CI: 92.3-96.4) for children 
<18 months of age but failed to detect 25 HIV-exposed children, including 3 HIV-
exposed children <3 months of age. In children <3 months of age, the WHO standard 
was almost attained by the Determine RT with a sensitivity of 98.7% (95% CI 96.2-
99.6) and a positive likelihood ratio of 37.5. Amongst the other HIV RTs, Reveal 
was an outlier with very low sensitivity of 38.7% (95% CI 34.4-43.2) <18 months of 
age and 56.3% (95% CI 49.7-62.7) <3 months of age whereas the sensitivity of Insti, 
Abon, SD Bioline and Advanced Quality RTs ranged between 72.8-86.2% and 94.9-
98.2% for children <18 months of age and children <3 months of age respectively. In 
a subset of 75 children <18 months of age who underwent testing with the Determine 
RT on plasma in the routine HIV testing laboratory at the CT study site, the 
sensitivity for detection of HIV exposure (HIV ELISA+) was 98.7% (95% CI 92.8-
99.8). This is in keeping with other studies that have shown a higher sensitivity of 
screening with HIV RTs when using plasma compared to whole blood. 42,43 
However, outside of laboratory settings where centrifuge facilities are available, 
most HIV testing makes use of whole blood from venesection or capillary blood 
samples.  
The sensitivity of antibody screening in children <18 months of age reduces with age 
as the rate of seroreversion increases. In this study, the sensitivity of the HIV RTs for 
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detection of HIV exposure (HIV ELISA+) in children aged 4-18 months ranged 
between 20.7% (Reveal RT) and 88.5% (Determine RT). Between 6 and 9 months of 
age, all the HIV RTs had sensitivity <65% except the Determine RT (88.8% [95% 
CI 80.0-94.0]). Between 9 and 12 months of age, all 6 HIV RTs had sensitivity for 
detection of HIV exposure <60% but confidence intervals were wide due to 
relatively low numbers of children undergoing testing in this age group. By 15-18 
months of age all the HIV RTs except Reveal (45.5% [95% CI 21.3-72.0]) had 
sensitivity of 100% although with wide confidence intervals due to low numbers. By 
far the majority of children in the 15-18 month age category were true positive (HIV 
RT+, HIV PCR +) or true negative (HIV RT-, HIV PCR-) results but there were 6 
false negative (HIV RT-, HIV PCR+) results (all Reveal) and 7 false positive results 
(Insti, Abon, Advanced Quality each 1, and Determine 4).  
In the evaluation of specificity of the HIV RTs for exclusion of HIV exposure, 
assessed in the HIV-unexposed (HIV ELISA-) children <18 months of age, the Insti, 
Reveal, SD Bioline and Advanced Quality RTs all achieved the WHO-recommended 
minimum specificity of 98%. The specificity of the Determine RT was 93.1% (95% 
CI 90.1-95.2) and the Abon RT was 93.6% (95% CI 93.6-98.6). In children <3 
months of age only the Determine RT had specificity of <98% (97.4% [95% CI 
92.6-99.1]). The implication of these findings is that using the Determine or Abon 
RTs to screen for HIV exposure in children <18 months of age on whole blood 
would detect a greater number of false positive (HIV RT+, HIV ELISA-) results than 
with the other HIV RTs. This would necessitate more HIV PCR tests in order to 
exclude HIV infection than with the other HIV RTs. In the subset of 75 children <18 
months of age in whom the Determine RT was performed on plasma, the specificity 
was >98%. 
The performance of HIV RTs in detecting seroreversion while at the same time not 
missing any HIV-infected children is important in the decision of how best to use 
HIV RTs for excluding HIV infection among HIV-exposed children <18 months of 
age. Screening of HIV exposed infants at around 9 months of age with an HIV 
antibody test, as recommended by WHO, provides 2 important public health 
opportunities. Firstly, if the HIV antibody test result on the infant is positive, a 




virological test is required to identify HIV-infected infants who need cART. 
Secondly, the use of a sensitive and specific HIV RT at around 9 months of age 
could exclude HIV infection among well HIV-exposed infants who have not 
breastfed in the previous 6 weeks and provide a same-day result to the infant’s 
caregiver without the need for expensive HIV PCR testing which usually requires the 
caregiver to return to the healthcare facility days to weeks later for the result.  
 
This study showed seroreversion rates among HIV-exposed and uninfected (HIV 
ELISA+, HIV PCR-) children at 8-10 months of age of >80% for all the HIV RTs 
other than Determine (41.2%). By 10-12 months of age, the seroreversion rate was 
≥75% for all the HIV RTs. There were 6 HIV PCR+ children in the 10-12 month age 
category that were tested with the Insti, Reveal, Advanced Quality and Determine 
RTs, 5 that were tested with the Abon RT and 1 tested with the SD Bioline RT. 
Other than the Reveal RT that missed one HIV-infected child, all the other HIV RTs 
detected all the HIV-infected children in the 10-12 month age category. These 
findings indicate that it would have been possible to accurately exclude HIV 
infection by screening with the Insti, Abon, SD Bioline, Advanced Quality or 
Determine RTs without the need for HIV PCR testing in at least 75% of the infants 
aged 10-12 months although breastfeeding infants would still require further testing 
after weaning. Unfortunately the low numbers of HIV-exposed and uninfected 
children in the 8-18 month age categories (32) and HIV PCR + children in the 10-12 
month age category (6) limit the statistical certainty of these findings.  
 
Overall, 3 of the HIV RTs missed HIV-infected children (HIV PCR+, HIV RT-) <18 
months of age: Reveal (27/65, 41.5%), SD Bioline (1/22, 4.5%), and Insti (1/68, 
1.5%). In children <3 months of age, the Reveal RT missed 6/16 (37.5%) HIV-
infected children and the other HIV RTs detected 100% of HIV-infected children.  
 
Although meeting neither the WHO sensitivity nor the specificity criteria for the <18 
months age group as a whole, the Determine RT showed the best overall 
performance of the 6 HIV RTs evaluated. It showed the highest sensitivity for 
detecting HIV exposure and did not miss any HIV-infected children. Due to its high 
sensitivity, the Determine RT is able to detect lower amounts of circulating maternal 
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antibody in the infant plasma for longer than most other HIV RTs and therefore, 
when using the Determine RT to exclude HIV infection in HIV-exposed children 
<18 months of age, seroreversion (loss of maternal antibody) may be detected at a 
later age than with other HIV RTs as antibody levels wane to even lower levels. 
Therefore, false-positive results (in comparison to laboratory HIV ELISA testing) 
may occur and HIV PCR testing may be more frequently required to exclude HIV 
infection than with other HIV RTs. 
Children ≥18 months of age 
In children ≥18 months of age, the WHO recommended sensitivity of ≥99% in 
comparison to laboratory HIV ELISA for diagnosis of HIV infection was attained for 
3 of the HIV RTs (Abon, SD Bioline and Determine all 100%) although confidence 
intervals were wide due to the small numbers of HIV-infected children in this age 
category. All the HIV RTs met the WHO specificity criterion and were found to 
have a specificity of 100% for excluding the diagnosis of HIV infection. The 
implication of these findings is that in a serial testing algorithm for the diagnosis of 
HIV infection in children ≥18 months of age, any of the 3 more sensitive HIV RTs 
(Abon, SD Bioline and Determine) can be recommended as the initial test, and any 
of the HIV RTs (which all showed high specificity for HIV infection) can be 
recommended as the confirmatory test (with the exception of the Reveal RT due to 
its very low sensitivity).  
Comparison with published studies 
This study confirms the finding of previous studies that all HIV RTs do not perform 
equally in infants and young children and contributes new data on HIV RTs not 
previously evaluated in very young children. There is a lack of published literature 
on the performance of the Reveal, Abon, SD Bioline and Advanced Quality HIV 
RTs in an infant or paediatric population against which to compare the findings of 
the present study.  However, Sherman evaluated 2 of the HIV RTs included in this 
study, Determine and Insti, in 2 previous studies.  
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In the first Sherman study (2008), the sensitivity of the Determine and Insti RTs for 
the detection of HIV exposure in children <12 months of age was 99.7% (95% CI 
99.0-100.3) and 79.9% (95% CI 75.5-84.2) respectively, slightly higher than the 
sensitivity of 95.1% (95% CI 92.7-96.7) and 72.1% (95% CI 67.9-76.0) respectively 
in children <12 months of age in the present study. 43 One of the reasons for this 
difference may be that in the Sherman study HIV RTs were performed on samples 
from HIV-exposed infants taken at 4 time points (1.5, 3, 7 and 12 months) as 
compared to testing across all ages in children <12 months in the present study. 
Another reason may be that in the Sherman study, HIV RTs were performed on 
stored plasma or serum whereas in the present study testing was performed on whole 
blood. The sensitivity of HIV RT’s has been reported to be higher when performed 
on plasma or serum rather than whole blood. 42,43  
In the second Sherman study (2012), in which HIV RTs were performed on whole 
blood, the sensitivity of the Determine RT for the detection of HIV exposure in 
children <18 months of age and <3 months of age was 95.5% (95% CI 93.5-96.9) 
and 99.3% (95% CI 98.0-99.8) respectively which was similar to the findings in the 
present study of 94.7% (95% CI 92.3-96.4) and 98.7 (95% CI 96.2-99.6) 
respectively. 42 However, the sensitivity of the Insti RT was considerably lower in 
the present study (72.8% (95% CI 68.6-76.5) and 94.9% (95% CI 91.3-97.0) in 
children <18 months and <3 months of age respectively) compared to the Sherman 
study (95.7% (95% CI 92.4-97.6) and 98.7% (95% CI 96.2-99.6). 42 This is likely to 
be a reflection of the larger sample size in the present study. 
Regarding specificity for exclusion of HIV exposure in children <18 months of age, 
the present study found Determine to have a lower specificity (93.1% (95% CI 90.1-
95.2) than was found in the Sherman 2012 study (99.2% (95% CI 95.6-99.9) 
reflecting a higher rate of false-positive Determine RT results in the present study. 
For the Insti RT, a slightly higher specificity was found in the present study (99.3% 
(95% CI 97.9-99.8) compared to the Sherman study (96.2% (95% CI 87.0-98.9)). 42  
The seroreversion rate for the Determine RT at 8-10 months of age was 41.2% (7/17) 
in the present study versus 81.8% (9/11) in the Sherman 2012 study despite the 




sensitivity of the Determine RT for detection of HIV exposure being similar in the 2 
studies. Regarding the Insti RT, the seroreversion rate was 100% (17/17) at 8-10 
months of age in the present study but there no data available in this age category in 
the Sherman 2012 study. However, in the 6-8 month age category, the seroreversion 
rate for the Insti RT was 77.6% (45/58) in the present study versus 100% (2/2) in the 
Sherman study. 42 Reasons for the different seroreversion rates between the 2 studies 
include the small sample sizes in these age categories, particularly in the Sherman 
study, and the possibility that in the present study (conducted between 2011-2014) 
there may have been greater infant exposure to maternal cART during pregnancy or 
breastfeeding than in the 2012 Sherman study. Maternal cART during pregnancy has 
been associated with delayed seroreversion among HIV-exposed but uninfected 
children. 15 
 
The ability of the Determine RT to detect HIV-exposed and infected (HIV ELISA+ 
HIV PCR+) children <18 months of age was 100% both in the present study (65/65) 
and in the De Baets study (116/116) but 93.1% (54/58, 4 HIV-infected children 
missed) in the study by Menzies et al. and 96.3% (105/109, 4 HIV-infected children 
missed) in the Sherman 2012 study 41,42,46 One of the differences between the present 
study and the De Baets studies on the one hand and the Menzies and Sherman 2012 
studies on the other hand is that the HIV prevalence rate in the <18 month age 
category differs: 9.6% and 8.5% versus 25.6% and 18.8% respectively. This suggests 
that HIV-infected children <18 months of age are more likely to be missed using 
HIV antibody tests for screening in settings with higher HIV prevalence. 
Interestingly, of theses 4 studies, only the current study included children with acute 
illness attending or admitted in a paediatric hospital, a setting in which one may 
expect lower HIV antibody levels to be present in the child’s circulation, but despite 
this no HIV-infected children were missed by the Determine RT. In the present 
study, the Insti RT missed 1 HIV-exposed and –infected child (1/68, 1.5%) and in 
the Sherman 2012 study, Insti detected 100% (32/32). 42 
 
Among children ≥18 months of age, the sensitivity and specificity results of the HIV 
RTs for the detection of HIV infection were comparable with other published studies 
with some variation with differing HIV prevalence rates in the study populations. 
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The sensitivity of the Determine RT was 100% in the present study (HIV prevalence 
rate 4.9%) and in the De Baets and Sherman (2012) studies (HIV prevalence rates of 
3.9% and 64% respectively). The specificity of the Determine RT was 100% in the 
present study and in the De Baets study, and 97.5% (95% CI: 87.1-99.6) in the 
Sherman 2012 study (HIV prevalence 64%). 41,42 The sensitivity of the Insti RT was 
92.3% (95% CI: 66.7-98.6) in the present study (HIV prevalence 4.9%), and 100% in 
the Sherman study (HIV prevalence 43%) while the specificity was 100% in the 
present study and 93.8% (95% CI: 71.7-98.9) in the Sherman study. 42      
Strengths and limitations 
The present study has a number of strengths and limitations as indicated in the 
STARD checklist (Appendix 4). 63 The diagnostic accuracy of 6 HIV RTs used for 
HIV testing of children in South African health care facilities was rigorously 
evaluated in 2 accredited, quality-assured hospital laboratories thereby meeting the 
stated aims and objectives of the study. At each of the 2 study sites, a single 
experienced laboratory technologist performed all study HIV RTs according to the 
manufacturer’s instructions. Whole blood rather than stored plasma or serum 
samples were used in the study so that the results obtained would be more 
generalizable to HIV testing contexts where centrifugation facilities are not available 
and whole blood samples are used for HIV rapid testing. Results of testing using the 
Determine RT on plasma were also available from the routine HIV testing laboratory 
for a subset of children at the CT study site and this allowed comparison of 
sensitivity and specificity performance between plasma and whole blood. The study 
design was prospective, based on the use of leftover blood samples from children 
with a wide range of ages that were in the process of undergoing HIV testing at the 
time, and as a result was efficient and cost saving. This avoided the need to recruit 
and enrol individual children onto the study, obtain informed consent for study 
participation from parents or legal guardians, or to subject children to venesection 
purely for study purposes. The reporting of this study followed the 2015 STARD 
methodology, a published international consensus approach to maximise the 
completeness and accuracy of reporting diagnostic accuracy studies. 63 The study 
was able to propose evidence-based recommendations on the future clinical role of 
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the index tests (HIV RTs) that were evaluated for HIV testing of infant and young 
children.   
The limitations of this study have been identified by using the 2015 STARD 
checklist (Appendix) and relate mostly to the study design and setting. 63 The study 
design was based on the use of leftover blood from children undergoing routine HIV 
testing at 2 different study sites. Since the study did not enrol individual study 
subjects, recruitment of study samples depended on the number of children 
undergoing HIV testing at the 2 study sites, the submission of appropriate samples to 
the laboratory by clinicians, and availability of adequate volumes of leftover blood to 
use for performing the HIV ELISA test and HIV RTs. The study had no influence 
over which children underwent HIV testing and at what ages. The duration of the 
study was based on a convenience sample and funding availability. 
The rate of recruitment of leftover blood samples was considerably slower than was 
anticipated. At the CT study site, this was as a result of very small blood volumes 
being submitted to the laboratory by clinicians at RCWMCH and the common 
practice of requesting the laboratory to perform HIV testing on an EDTA blood 
sample that was previously submitted for a full blood count. In response to the slow 
recruitment of adequate volume samples it was decided to include the use of plasma 
or serum leftover from biochemistry assays on the same child at the same time as the 
HIV test request in order to perform the study HIV ELISA test when required, and 
this improved the availability of adequate volumes of EDTA sample for the study 
HIV RTs to a certain extent. At the Jhb study site, inadequate blood sample volumes 
were responsible for many of the invalid HIV ELISA and HIV RTs.     
Withdrawal of the SD Bioline RT by the SA NDOH during the course of the study 
and the replacement with the Abon RT resulted in a lower number of samples being 
evaluated with these 2 HIV RTs.  
HIV PCR testing was not routinely performed on the children who tested negative 
with the routine Determine RT at the CT study site, as this is not included in the 
routine HIV testing algorithm and the CT study was not funded to allow HIV PCR 
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testing on all children. Lack of HIV PCR test results (21% of children <18 months of 
age) impacted on the calculation of HIV prevalence rate and seroreversion rate, and 
assessment of the ability of the HIV RTs to detect HIV-exposed and –infected 
children. In addition, the performance of the 6 HIV RTs for the detection of HIV-
infected children was evaluated in comparison to a single positive HIV PCR result 
for children <18 months of age and a single positive laboratory HIV ELISA result 
for children ≥18 months of age. These were pragmatic definitions of HIV infection 
adopted for this study but do not concur with standard definitions of HIV infection 
that requires 2 positive HIV PCR tests in children <18 months of age and 2 positive 
HIV ELISA (or HIV RT) tests in children ≥18 months of age on 2 separate samples. 
9,28-31
Among children <18 months of age, there was a wide discrepancy in the sample size 
of younger children (<9 months of age) compared to older children (9-18 months of 
age) undergoing HIV testing. This partly reflects the widespread access to EID with 
HIV PCR testing in South Africa. South African HIV treatment guidelines published 
during the time this study was performed recommended initiation of cART for all 
HIV-infected children <5 years of age. As a result there are relatively few children 
between 9 and 18 months of age whose HIV status is unknown and who still require 
HIV testing. Successful implementation of the Prevention of Mother To Child 
Transmission (PMTCT) programme has resulted in significant reductions in the 
number of HIV-infected infants and young children. 6 The lower than anticipated 
numbers of HIV-exposed and HIV-infected children in the 9-18 month age category 
resulted in statistical uncertainty regarding the analysis of seroreversion rates and the 
ability of the HIV RTs to detect HIV-exposed and infected children in this age 
group.  
HIV testing of infants and children takes place in a wide array of clinical settings 
including primary care clinics and hospitals with different laboratory infrastructure 
and is performed in infants and children with different prevalence rates of HIV 
exposure and HIV infection who may be clinically well or who have severe disease. 
The setting of this study was hospital-based and therefore not likely to be 




representative of all other HIV testing settings. This limits the generalizability of the 
findings of this study to similar settings.  
 
There were some differences between the 2 study sites. At the CT study site, leftover 
blood samples were obtained from children undergoing screening for HIV exposure 
and HIV infection according to a clinical algorithm applied to a hospital environment 
whereas at the Jhb study site leftover blood samples were obtained from children 
undergoing HIV PCR or HIV VL testing. Samples from children ≥18 months of age 
were obtained almost exclusively from the CT study site. The prevalence of HIV 
exposure and HIV infection may have differed between the 2 study sites but since 
the data from the 2 study sites was combined into a single dataset for the statistical 
analysis, the prevalence rate of HIV exposure and HIV infection was not calculated 
separately for the 2 sites. Small sample sizes, particularly in the 9-18 month age 
group precluded meaningful separate statistical analysis of the data from each study 
site.  
 
The study design did not make provision for the collection and/or verification of the 
following demographic data relating to each of the children whose blood samples 
were included in the study: clinical condition of the child, maternal HIV status, 
maternal cART, infant feeding modality (breastfeeding and/or infant formula 
feeding), and exposure of the infant or child to ARV prophylaxis or treatment. Based 
on the submission of a blood sample for routine HIV testing to the laboratory at 
RCWMCH or for HIV PCR testing at the Jhb study site it was assumed that the child 
was not currently receiving cART but some children, particularly infants <6 weeks 
of age and breastfeeding HIV-exposed children of all ages, may have been receiving 
nevirapine as prophylaxis against acquiring HIV infection. Exposure to ARVs in the 
form of infant nevirapine or via maternal ARVs excreted in breastmilk may have 
impacted on the detection of HIV antibodies by HIV ELISA and/or HIV RT as well 
as the HIV PCR test result in the infant. Reduced sensitivity of HIV PCR testing in 










Despite the importance of HIV virological tests in confirming HIV infection in 
children <18 months of age, HIV RTs have an important role in screening children 
<18 months of age for HIV exposure in order to detect which children require further 
virological testing and in which children HIV infection can be excluded without 
further testing. Among children ≥18 months of age, HIV RTs generally perform well 
in the diagnosis of HIV infection, as in adults. 
 
This study has shown that the diagnostic accuracy of HIV RTs for the detection and 
exclusion of HIV exposure among children <18 months of age, the age at which 
seroreversion amongst HIV-exposed uninfected infants and young children occurs, 
and the ability to detect HIV-infected infants and young children <18 months of age 
differs between different HIV RTs.  
 
The findings of this study support the current HIV testing algorithm adopted by the 
Western Cape Province Department of Health and RCWMCH which recommends 
the use of the Determine RT for the initial screening of a child with unknown HIV 
status and in whom the current maternal HIV status is unknown. 
 
Ongoing research and evaluation of the performance of different HIV RTs among 
infants and young children is needed. This research should include breastfed HIV-
exposed infants and include infants and young children with exposure to maternal 
cART during pregnancy and breastfeeding. HIV RT performance should also be 
further evaluated in health care settings where personnel other than trained 





• Among the 6 HIV RTs evaluated in this study, the Determine RT is
recommended as the preferred HIV RT for screening children <18 months of
age as it showed the highest sensitivity in comparison to laboratory HIV
ELISA and despite failing to detect 25 HIV-exposed children, including 3
HIV-exposed children <4 months of age, no HIV-infected children were
missed (all 25 HIV-exposed children were HIV PCR negative). The
sensitivity of the Determine RT was even higher on plasma compared to
whole blood samples and where laboratory facilities are available plasma
should be the preferred sample on which to perform HIV RTs for screening
infants and young children.
• In addition to the Determine RT, the SD Bioline, Abon and Advanced
Quality RTs can be recommended for screening children <3 months of age as
all 3 showed sensitivity and specificity for detection or exclusion of HIV-
exposed infants in this age group of >97% and >99% respectively and no
HIV-infected infants were missed. It is important to bear in mind that not all
the children in this study had HIV PCR testing performed and so it is
possible that some HIV-infected infants and young children were not
detected by some or all of the HIVRTs.
• Besides infants <3-4 months of age, routine screening of HIV-exposed
infants is recommended at around 9 months of age. Although in this study all
6 HIV RTs detected all HIV-infected children aged 8-10 months, very small
sample sizes result in significant statistical uncertainty about this result.
• Similarly, small sample sizes prevent a strong and generalizable
recommendation to be made on the preferred HIV RT for early and accurate
detection of seroreversion among HIV-exposed uninfected infants and young
children. Seroreversion was detected earlier with the INSTI and Advanced
Quality RTs (Insti missed only 1 HIV-infected child and the child was 3-4




months of age) and later with the Determine RT than with any of the other 
HIV RTs evaluated.  
 
• Among children ≥18 months of age, the SD Bioline, Abon or Determine RT, 
may be recommended as initial screening tests for the diagnosis of HIV 
infection as all 3 were shown to be 100% sensitive in comparison to 
laboratory HIV ELISA. The Insti and Advanced Quality RTs did not achieve 
adequate sensitivity to allow them to be recommended as initial screening 
tests but these results do not concur with their performance in other 
evaluations and may reflect the small sample size in this study. Other than the 
Reveal RT that was found to have very low sensitivity, any of the other 5 
HIV RTs can be recommended as confirmatory tests for HIV diagnosis in 
children ≥18 months of age. 
 
• Current South African NDOH HIV guidelines do not specify which HIV RTs 
should be used for HIV screening in children <18 months of age. Based on 
this and other studies, the evaluation of the diagnostic accuracy of specific 
HIV RTs in infant and paediatric populations should be a pre-requisite for 
consideration of inclusion in NDOH HIV RT tenders and use in HIV testing 
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studies and the development of new diagnostic assays. This blanket approval 
covers projects that will make use of residual routine specimens received by the 
NHLS for routine diagnostic testing. Once the routine testing is complete, R&D 
has access to these specimens. No additional patient specimens are received for 
the R&D testing. To date this approval has been granted for projects such as CD4 
validation, HIV viral load validation, serology validations, coagulation assay 
development etc. 
We would like to add another R&D project to this list: 
Project title:  The evaluation of seven commercially available Rapid HIV test 
performance on whole blood in HIV-exposed infants and children to establish 
suitability for an HIV diagnostic algorithm in infants and children.  
In 2011, the South African Department of Health adopted a policy of exclusive 
breastfeeding in HIV-exposed infants. An evidence-based diagnostic algorithm to 




detect postnatal transmission of HIV is yet to be defined. This study aims to 
provide evidence to support such an algorithm. 
 
The project has two objectives: 
1. To determine the seroreversion (i.e. loss of maternal HIV antibodies) rate for 
each Rapid HIV test in children to exclude HIV infection. 
2. To determine the frequency of loss of HIV antibodies (resulting in false 
negative rapid tests) in HIV-exposed and infected infants due to early initiation of 
antiretroviral therapy. If these children were inadvertently tested and false 
negative rapid test results obtained, there life-saving antiretroviral therapy may 
be erroneously discontinued. 
Residual specimen from samples sent to the department’s laboratories for HIV 
PCR, Viral load and occasionally CD4 testing will be submitted for an HIV ELISA 
test (to act as a reference standard for comparison to the rapid test results) and 
seven rapid HIV tests. No additional samples from the patient will be required 
and any additional costs incurred will be for the study’s account. No patient 
identifying details will be captured however, for the 2nd objective the date of 
antiretroviral therapy initiation (if captured) on the laboratory information 
system may be required to be recorded for the data analysis of test 
performance. 
 
Investigators: The PI for this study is Prof Gayle Sherman from the department of 
Molecular Medicine and Haematology University of Witwatersrand Medical 
School. The rapid HIV tests will be performed by Ms Kapila Bhowan (registered 
technologist). 
 
I am happy that this project complies with the departmental R&D global program 
and we request this project to be included in the R&D programme under ethics 
number (M09-06-88). 
 




Prof Lesley Scott, PhD 
Senior Medical Scientist 
Department of Molecular Medicine and Haematology 
University of the Witwatersrand, Johannesburg,  
South Africa lesley.scott@nhls.ac.za,  
011-489-8565 
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Item Item reported 
in this study 
(page number) 
Title or abstract Identification as a study of diagnostic accuracy using 
at least one measure of accuracy (such as sensitivity, 
specificity, predictive values or AUC) 
Yes (1) 
Abstract Structured summary of study design, methods, results, 
and conclusions 
Yes (8) 
Introduction Scientific and clinical background, including the 
intended use and clinical role of the index test 
Yes (12) 
 Study objectives and hypotheses Yes (43) 
Methods   
Study design Whether data collection was planned before the index 
test and reference standard were performed 
(prospective study) or after (retrospective study) 
Yes (41) 
Participants Eligibility criteria Yes (44) 
 On what basis potentially eligible participants were 
identified (such as symptoms, results from previous 
tests, inclusion in registry) 
Yes (44) 
 Where and when potentially eligible participants were 
identified (setting, location, and dates) 
Yes (44) 
 Whether participants formed a consecutive, random or 
convenience series 
Yes (46) 
Test methods Index test, in sufficient detail to allow replication Yes (44) 
 Reference standard, in sufficient detail to allow 
replication 
Yes (43) 
 Rationale for choosing the reference standard (if 
alternatives exist) 
Yes (74)* 
 Definition of and rationale for test positivity cut-offs 
or result categories of the index test, distinguishing 
pre-specified from exploratory 
Yes (47) 
 Definition of and rationale for test positivity cut-offs 
or result categories of the reference standard, 
distinguishing pre-specified from exploratory 
Yes (47) 
 Whether clinical information and reference standard 
results were available to the performers/readers of the 
index test 
Yes (45) 
 Whether clinical information and index test results 
were available to the assessors of the reference 
standard 
Yes (45) 
Analysis Methods for estimating or comparing measures of 
diagnostic accuracy 
Yes (48) 
 How indeterminate index test or reference standard 
results were handled 
Yes (48) 
 How missing data on the index test and reference 
standard were handled 
Yes (48) 
 Any analyses of variability in diagnostic accuracy, 
distinguishing pre-specified from exploratory 
Yes (48) 
 Intended sample size and how it was determined Yes (46) 
Results   
Participants Flow of participants, using a diagram Yes (57) 
 Baseline demographic and clinical characteristics of 
participants 
No 




 Distribution of severity of disease in those with the 
target condition 
No 
 Distribution of alternative diagnoses in those without 
the target condition 
No 
 Time interval and any clinical interventions between 
index test and reference standard 
No 
Test results Cross tabulation of the index test results (or their 
distribution) by the results of the reference standard 
Yes (60) 
 Estimates of diagnostic accuracy and their precision 
(such as 95% confidence interval) 
Yes (60) 
 Any adverse events from performing the index test or 
the reference standard 
No 
Discussion   
 Study limitations, including sources of potential bias, 
statistical uncertainty, and generalizability 
Yes (73) 
 Implications for practice, including the intended use 





 Registration number and name of registry No 
 Where the full study protocol can be accessed No 
 Sources of funding and other support; role of funders Yes (46) 
 
* This is discussed as a limitation of the study in the Discussion section not the Methods section 
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